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ABBREVIATIONS AND SYMBOLS 
1D one-dimensional 
2D two-dimensional 
APCI atmospheric pressure chemical ionization 
COSY correlated spectroscopy 
cryst crystallization 
δ chemical shift 
ee enantiomeric excess 
fr fraction 
GF gel filtration 
HMBC heteronuclear multiple-bond correlation spectroscopy 
HSQC heteronuclear single-quantum coherence spectroscopy 
HPLC high-performance liquid chromatography 
HRE(S)IMS high-resolution electron (spray) ionization mass spectroscopy 
JMOD J-modulated spin-echo experiment 
NMR nuclear magnetic resonance 
MS mass spectroscopy 
MPLC medium pressure liquid chromatography 
NOE nuclear Overhauser effect 
NOESY nuclear Overhauser enhancement spectroscopy 
NP normal phase 
OCC open-column chromatography 
Rf retention factor 
RP reversed phase 
RPC rotation planar chromatography 
PLC preparative thin-layer chromatography 
TLC thin-layer chromatography 
TMS tetramethylsilane 
tR retention time 
UV ultraviolet 
VLC vacuum-liquid chromatography 
  
2 
1. INTRODUCTION 
The family Juncaceae comprises about 500 species worldwide, which are distributed into seven 
genera.1-3 Species of the family are widely distributed on both hemispheres, from arctic regions to the 
subtropics, but sporadically they are occurring in tropic regions as well.4 Most of the Juncaceae species 
grow exclusively in wetland habitats (i.e. rice lands, marshes). The two largest, cosmopolitan genera 
of the family are Juncus L. (n = 347) and Luzula DC. (n = 115).5 There are 15 Juncus and 6 Luzula species 
native to Hungary.6 
Because of the global distribution of the Juncaceae plants, the species are used worldwide, but 
mainly in the Asian folk medicine. Various Juncus species (e.g. J. effusus, also known as “Dengxincao”) 
are used in the traditional Chinese medicine for the treatment of numerous disorders. The spectrum 
of indications is quite wide; in the folk medicine the tranquilizing effects (e.g. sedative-hypnotic, 
anxiolytic) on the central nervous system are well known.7-10 Furthermore, Juncus species are also used 
in the treatment of cold, fever and inflammation.11 The seeds of J. rigidus are consumed in Egypt in 
order to treat diarrhoea and diuretic disorders.12 In Basque regions, the stems of J. conglomeratus, 
J. effusus and J. inflexus were used in rituals against warts and other skin diseases.13,14 The aerial parts 
of J. balticus and J. effusus and the roots of J. ensifolius were consumed as healthy foods by indigenous 
peoples in Canada.15 The traditional usage of plants belonging to other genera of the family has not 
been reported yet. 
Several Juncaceae species have economic significance. Juncus plants (e.g. J. acutus, J. arabicus, 
J. rigidus) have been used to make mats, mattresses, sandals and baskets throughout Africa since 895 
B.C.16-18 J. kraussii is a valuable source of fibre among Zulus; bridal sleeping mats and baskets are 
weaved from the culms of the plant.19 Great deals of Juncus species are native to South-America, 
therefore these plants (e.g. J. arcticus var. andicola, J. effusus, J. ramboi subsp. colombianus) are 
commonly used in that region in order to prepare traditional craftworks.20 Some species, such as 
J. acutus, J. rigidus, and few Luzula species were used in the paper industry.21 
The most characteristic compounds identified in the species of family Juncaceae are 
phenanthrenes and 9,10-dihydrophenanthrenes.22 To date, almost one hundred novel phenanthrenes 
have been isolated from the family, but only from Juncus species.23-31 Although many phenanthrene-
containing species have been used in folk medicine for hundreds of years in order to treat several 
diseases, however the chemical composition and the mechanism of action of many of these plants 
have not been studied thoroughly yet. Therefore, these plants and their secondary metabolites are 
worthy of future investigations. Phenanthrenes have drawn considerable interest from the aspect of 
natural product drug discovery because of the wide range of their potentially valuable biological 
activities (e.g. antitumor, antibacterial, anti-inflammatory, antioxidant, anxiolytic, cell-protective, 
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sedative, and spasmolytic activities) and their broad structural diversity.7-9,11,23,27-35 Probably, the most 
investigated naturally occurring phenanthrene derivate is denbinobin, which displays remarkable anti-
tumour activity against several cancer cell lines. Moreover, its anti-HIV property is also very 
promising.36-38 
In 2014, a research group of the Department of Pharmacognosy, University of Szeged initiated 
a research program with the aim of investigating the secondary metabolites of Juncaceae species. This 
program involved the phytochemical and pharmacological investigation of 19 Juncaceae species, and 
preparative phytochemical work was performed with the most promising species, namely 
Juncus inflexus and Luzula luzuloides. The present thesis summarizes the results of this work. 
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2. AIMS OF THE STUDY 
The family Juncaceae is an abundant source of bioactive phenanthrenes. A few years ago a research 
program has been started in the Department of Pharmacognosy, University of Szeged with the aim of 
investigating the secondary metabolites of plants belonging to the family Juncaceae. The objectives of 
the present work – as part of this project – were isolation and structural characterization of 
phenanthrenes, and investigation of their pharmacological effects. 
In order to achieve the aims, the main tasks of the presented study were: 
• Review the literature of the naturally occurring phenanthrenes. 
• Overview the chemical and pharmacological properties of the plants of the family Juncaceae. 
• Collection of Juncaceae plant samples (altogether 19 species) from the Carpathian Basin. 
• Preparation of extracts with different polarity in order to perform pharmacological and 
chemical screening of the extracts of Juncaceae species. 
• In vitro screening of the extracts for antibacterial effect on resistant bacterial strains, and 
determination of MIC values of the active extracts. 
• In vitro screening of Luzula species for anti-inflammatory effects on fMLP/CB-induced human 
neutrophils. 
• Detailed phytochemical analysis of Juncus inflexus and Luzula luzuloides, using a bioactivity-
guided approach to identify active fractions and components. 
• Provide characteristic spectral data on the isolated compounds. 
• Structure elucidation of the isolated components. 
• Determination of the absolute configuration of the chiral compounds. 
• Evaluation of the pharmacological potential and chemotaxonomical relevance of the isolated 
compounds. 
• Prediction of possible biosynthetic pathways by semi-synthetic approaches. 
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3. LITERATURE OVERVIEW 
3.1. BOTANY OF THE FAMILY JUNCACEAE AND THE INVESTIGATED SPECIES 
The monocotyledonous Juncaceae plants are usually perennial herbs, but some representatives are 
annual. From the creeping rhizomes of the plants, short lived leafy shoots (culms) grow that end in an 
inflorescence, but the rhizome is sometimes reduced or lost. Several leaves cluster around the base of 
each culm, and sometimes along with it. The long, narrow leaves of the plants have sheathing base, 
but in some cases the leaves are reduced to scale-like structures on the rhizome. Juncus plants may 
have bifacial or unifacial leaves, and sometimes it can also be reduced to membranous sheaths. Species 
belonging to the genus Luzula can be recognised by the existence of closed-leaf sheaths and 
multicellular hairs on the leaves. Both genera have inflorescences with many flowers, the air-pollinated 
flowers are actinomorphic, hermaphrodite and protogynous. The flowers have six perianth-segments 
in two whorls. The number of ovules and type of placentation is also characteristic to Luzula species, 
because they have three basal ovules, whereas all of the other genera have numerous axile or parietal 
ovules. Juncaceae plants have dehiscent fruits and endospermic seeds.6,39 
Both investigated plants belong to the family Juncaceae, in the order Poales. Juncus inflexus L. 
belongs to the subgenus Juncus of the genus Juncus, and Luzula luzuloides (Lam.) Dandy & Wilmott 
belongs to the subgenus of Antheleae of the genus Luzula.39 
Juncus inflexus L. (hard rush, blue rush; syn. Juncus glaucus Sibth., Juncus longicornis Bast.) is a 
perennial, caespitose plant with a height of 50-120 cm. The basal sheaths are usually reddish-brown. 
The stems are grey-green in colour, and the pith is interrupted. The plant has only basal leaves, 
measuring 4-10 cm. The sheaths are brown to black in colour. The lax inflorescence is many flowered. 
The perianth-segments measure 2.5-4.0 mm, they are unequal, narrow ovate and acuminate. The 
flowers are green in colour. The brown seeds measure 0.5 mm; they are obliquely ovoid, reticulate. 
The shining brown capsules exceed or equal to the perinath, its shape may vary from trigonous-ovoid 
to trigonous-ellipsoid. The plant grows in fens, wet grasslands, and damp open habitats. It occurs 
throughout Europe, North-Africa and Asia.6,39 
Luzula luzuloides (Lam.) Dandy & Wilmott (forest wood rush, white wood rush; syn. 
Luzula albida (Hoffm.) DC., Luzula nemorosa (Pollich) E.Mey.) is a perennial, laxly caespitose plant with 
a height of 30-50 cm. The basal leaves are 3-6 mm wide, 30 cm long, flat, long-ciliate shaped. The 
corymbose inflorescence is lax or condensed with divaricate branches with clusters of 2-10 flowers. 
The perianth-segments measure 2.5-3.5 mm; they are white, but sometimes their colour is suffused 
with red. The dark brown, shining ellipsoid seeds measure 1.1-1.2 mm. The ovoid capsules are as long 
as the perinath-segments. The plant occurs in Europe and North-America. It grows in woods and 
meadows.6,39 
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3.2. CHEMICAL CONSTITUENTS OF THE FAMILY JUNCACEAE 
The Juncaceae family has been the subject of intense phytochemical examination in the past ten years. 
It can be explained with the fact, that the widely available plants of the family have been overlooked 
over decades. Despite of the comprehensive research focused on Juncaceae family, until now only 
species belonging to the genus Juncus were investigated extensively. The chemical constituents of the 
genus Luzula has not been discovered yet. 
Phytochemical investigations of Juncus plants resulted in the isolation of different secondary 
metabolites. Numerous coumarins [e.g. juncusyl ester A, (2S)-1-O-p-coumaroyl glyceride, 6-hydroxy-
7-methyl-5α,8α-benzocoumarin] and flavonoids (e.g. apigenin, apigenin 7-O-glucoronide, chrysoeriol, 
hydnocarpin, luteolin, nobiletin, quercetin) were identified from Juncus species.22,27,40-42 Carotenoids 
and steroids (β-sitosterol, stigmasterol, α-spinasterol) were also isolated from J. effusus, J. gerardii and 
J. bufonius.43,44 Several terpenoids, such as rosane-type diterpenes (e.g. effusenone A) and cycloartane 
triterpenes (juncusides I–V) were isolated from J. effusus.24,45,46 Among the isolated phenolic com-
pounds commonly occurring constituents (e.g. p-coumaric acid, vanillic acid) and more specific 
components, such as markhamioside F and canthoside B were reported.44,47 Stilbenes are considered 
to be the biosynthetic precursors of phenanthrenes and 9,10-dihydrophenanthrenes, therefore it is 
worth noting that oxyresveratrol 2-O-β-D-glucopyranoside and resveratrol 3’,4’-O,O’-di-β-D-
glucopyranoside were isolated from J. acutus.47 The most specific chemical constituents of the family 
Juncaceae are phenanthrenes and 9,10-dihydrophenanthrenes.22 The isolated compounds were 
obtained from different parts (aerial parts, medullae, rhizomes, roots, root bark, stems) of the plants. 
Genus Luzula, the second largest genus of the family, comprises around 115 species.48 However, 
there is a significant lack of information regarding the chemical constituents of the plants belonging to 
this genus. Before our study on L. luzuloides, only the flavonoid components of Luzula species were 
confirmed. As a result of an extensive research, several flavonoids were identified by comparison of 
their Rf values and colours with standards from eleven Luzula species (L. arcuata, L. campestris, 
L. confusa, L. forsteri, L. lactea, L. multiflora, L. nivea, L. nodulosa, L. nutans, L. pilosa, L. spicata and 
L. sylvatica). Luteolin and luteolin 7-O-glucoside were detected from all of the investigated Luzula 
samples.42 Quercetin, procyanidin and other luteolin derivatives (luteolin 5-methyl ether, luteolin 5-
methyl ether 7-O-glucoside) were also identified in some species. So far, only luteolin and luteolin 7-
O-glucoside were isolated by the use of preparative paper chromatography from Luzula species.49 
Therefore, flavonoids were considered to be the main secondary metabolites, and the most 
characteristic components of Luzula species. 
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Based on the previous literature data, flavonoids, phenanthrenes and 9,10-
dihydrophenanthrenes are the most specific chemical constituents of the members of Juncaceae 
family. 
3.2.1. Chemical properties of phenanthrenes 
3.2.1.1. Biosynthesis of phenanthrenes 
Phenanthrenes are considered to be important taxonomic markers, because of their limited 
occurrence.22 These rare secondary metabolites are derived from a specific biosynthetic pathway. 
According to the most accepted hypothesis, the phenanthrene skeleton can be formed by oxidative 
coupling of the aromatic rings of stilbene precursors.22 In 1983, FRITZEMEIER et al. proved that L-
phenylalanine is the key precursor in the biosynthesis of dihydrostilbenes and 
dihydrophenanthrenes. 50  From L-phenylalanine, almost all higher plants are able to synthesize 
malonyl-CoA, and CoA-esters of cinnamic acid derivatives. These compounds are the precursors of 
stilbenoids, but the occurrence of stilbene synthase, which catalyses the formation of stilbene skeleton, 
is very limited. Stilbene synthase-related enzymes catalyse great deals of biosynthetic transformations 
in plants. The transformation of dihydro-m-coumaroyl-CoA into dihydrostilbenes (bibenzyls) is 
catalysed by bibenzyl synthase.51 
The phenanthrene core could be generated from stilbenes by UV irradiation in the presence of 
oxidants.52,53 Thus, the hydroxylation/methylation patterns of at least one of the two benzene rings in 
most phenanthrenes correspond to the 3,5-disubstitution pattern of stilbenes.54 The biosynthesis of 
phenanthrenes can be induced by oxidative stress or fungal infection in higher plants. These cyclized 
metabolites are stronger antioxidant and anti-fungal agents than their stilbenoid precursors.55 Fungal 
infections can also contribute to the high content of dihydrophenanthrenes in Juncaceae species.56 
Besides stilbenoid origin, phenanthrenes could also have other biosynthetic precursors. In 1974, 
SZENDREI et al. presumed the existence of phenanthrene derivatives from morphine alkaloids.57 Their 
presupposition was proved to be correct; thebaol, isolated from opium, shares the same core 
structural elements as thebain. Later, new phenanthrene alkaloids were isolated from Cryptocarya 
crassinervia.58 These compounds are probably not derived through the polyketide pathway, because 
later, very similar aporphine alkaloids were isolated from the same plant.59 A carboxamide substituted 
phenanthrene was isolated from Aristolochia manshuriensis, which is presumably derived from 
aristolochic acid.60 Aristolochic acids form a special group of secondary metabolites; according to their 
structures these compounds are alkaloid-like phenanthrenes. During their biosynthesis from aromatic 
amino acids (e.g. tyrosine) two phenylethane units are formed.61 The coupling of the phenylethane 
units results norlaudanosoline, as an intermedier, from which norlaudanosoline aristolochic acid and 
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3,4-methyIenedioxy-8-methoxy-10-nitro-phenanthrene-1-carboxylic acid are derived. 62  Therefore, 
nitrogen containing phenanthrenes do not have a stilbenoid origin. 
Euphorbiaceae family is a great source of diterpenes, but the occurrence of phenanthrenes is 
rather sporadic in the family.22,63 It is presumed, that ethylated, oxymethylated and thiomethylated 
phenanthrenes reported from the family are not undoubtedly derived from stilbenes.64 Although the 
highly aromatized norditerpene trigonochinene E possesses a phenanthrene skeleton, it seems very 
likely that biogenetically this compound is a norditerpene.65 
3.2.1.2. Chemical characteristics of mono- and diphenanthrenes 
Phenanthrenes are occurring in both monomeric and dimeric forms, around 80% of the plant 
synthesized phenanthrenes are monophenanthrenes.22 The substituents and the saturation of the 
bond between C-9 and C-10 resulted in the diversity of the monomers. The structures of the dimers 
are determined by the types of the connecting monomers and the position of the linkage. 
The wetland Juncus plants are considered as valuable sources of nitrogen-free alkylated 
monophenanthrenes; the first example of this class was juncusol isolated from J. roemerianus.66 To 
date, more than 90 monomeric phenanthrenes have been identified from Juncus species, including 
J. acutus, J. effusus, J. roemerianus, J. setchuensis and J. subulatus.22-31 Most of the phenanthrenes 
were isolated from J. acutus and J. effusus, and these plants are the most investigated species among 
the Juncaceae plants. 
Among monomeric compounds phenanthrenes and 9,10-dihydrophenanthrenes are distributed 
almost equally, around 60% of the compounds are 9,10-dihydrophenanthrenes (Figure 1).22 Reviewing 
the substitutions of the phenanthrenes, it can be recognized that all of the naturally occurring 
phenanthrenes are substituted. Most of the substituents are linked at C-2 and C-7, but C-3, C-4 and C-
6 substitutions also occur. Substitution at positions C-9 and C-10 is very rare either in phenanthrenes 
and dihydrophenanthrenes.22 
  
Figure 1. Phenanthrene and dihydrophenanthrene skeletons 
Almost all of the naturally occurring phenanthrenes are substituted with hydroxy group or they 
can be O-glycosides, which suggests that those compounds were also hydroxylated biogenetically.67 
The hydroxy group is generally linked at C-2 or C-7. The second most common substituent is the 
methoxy group, mainly at positions C-2, C-4, C-5 and C-6. Only phenanthrenes isolated from the 
members of Juncaceae family have vinyl substitution, habitually at C-5. Therefore, vinylated 
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phenanthrenes can be considered as chemotaxonomic markers of Juncaceae species.22-31 Most of the 
Juncaceae phenanthrenes are substituted with methyl groups. Methyl substitutions were generally 
found at C-1 or C-7.22-31 In some cases, uncommonly substituted phenanthrenes were also reported. 
Hydroxyalkyl substitution also occurs among Juncus phenanthrenes. Several hydroxymethyl 
substituted phenanthrenes were isolated from plants belonging to the genus Juncus.26,31,69,71 
Hydroxyethyl substituted 9,10-dihydrophenanthrenes were obtained as minor constituents from 
J. acutus and J. effusus.68-71 A methoxyethyl derivative was isolated by DELLA GRECA et al. from J. acutus 
and J. effusus.68,70,71 Carboxyl substitutions are also quite rare among the monophenanthrenes, and a 
few carboxylated compounds were reported from J. acutus and J. effusus.9,68,71,72 Carbaldehyde and 
keto substituted dihydrophenanthrenes were also isolated from J. effusus.9,28,68,72 Symmetric 
derivatives are rather uncommon among naturally occurring phenanthrenes, recently a symmetric 
tetracyclic molecule, juncutol was obtained from J. acutus.23 Juncutol could be derived from effusol, 
which was previously reported from the same plant, through the coupling of C-4 and the methine 
carbon of the vinyl group. 
Monosaccharide (e.g. glucose) moiety can also link to the phenanthrene skeleton, but 
disaccharide substituted phenanthrenes, such as phenanthrene-glucoapioside and -glucorhamnoside 
were also reported from higher plants.73 So far only five phenanthrene glucosides were isolated from 
the Juncaceae family (effusides I-V).74 
Furan or pyran ring can attach to the phenanthrene core. DELLA GRECA et al. obtained a 
representative of phenanthrofurans from J. effusus.68 
Phenanthrenequinones were also isolated from several higher plants.75,76 The biosynthesis of 
these compounds is not fully established. Oxygenated phenanthrenes and abietane-type diterpenoids 
can provide analogous phenanthrenequinones and alkylated 1,4-phenanthrenequinones, 
respectively.77,78 Despite of the great structural diversity of these compounds, only one phenanthrene-
quinone was isolated from Juncaceae species so far.25 
   
effusol juncutol effususin D 
Monophenanthrenes can connect through their functional groups or directly via C–C coupling 
to form di- or triphenanthrenes. The monomers can be linked together at many different positions, 
usually C-1 is involved into the connection. The linking monomers have usually been isolated previously 
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from the same plant, or the same genus or the same family. Almost all of the monomer parts of the 
dimers have been isolated earlier, only a few examples are undiscovered yet. Understandably, these 
secondary metabolites are even more sporadic and unique than monophenanthrenes. 
It is worth noting that lately several novel diphenanthrenes were reported from Juncaceae 
species. Until now seven compounds were isolated from J. acutus, and four dimers were obtained from 
J. effusus.27,29,79,80 Among the Juncaceae diphenanthrenes, the hit rate of the symmetric compounds is 
very high. DELLA GRECA et al. isolated five dimeric dihydrophenanthrenes with unexpected structures 
from the rhizome of J. acutus.79,80 The hepta- or octacyclic skeleton of these compounds are unique 
among naturally occurring phenanthrenes. These compounds are probably considered to derive by the 
coupling of various 5-vinyl-9,10-dihydrophenanthrene derivatives through a vinyl and a hydroxy 
group.79,80 The dihydrophenanthrene dimers, effususin A and effususin D are homodimers of effusol. 
According to the proposed biosynthetic pathway effususin D is formed from two effusols, after losing 
their hydroxy group at C-7.29 Other dimers of the Juncus genus have at least one unsaturated 
phenanthrene ring in their structure. A dimer of juncusol and dehydrojuncusol was isolated from the 
rhizomes of J. acutus.80 Dehydroeffusol and effusol are linked at 8,3’ positions in effususin B.29 
Presumably, effususin C is a dimer of two 7,7’-dehydroxylated dehydroeffusols linked at the positions 
of the former hydroxy groups. In case of 8,8’-bidehydrojuncusol, two dehydrojuncusol units form a 
symmetric homodimer through an 8,8’ coupling.29 Phenanthrene dimers were described from different 
parts of the plants, therefore it seems that there is no specific plant organ where their synthesis would 
be more expressed. Juncaceae dimers were reported from the roots, rhizomes and medullae of the 
species. 
Some phenanthrenes (e.g. effusol, juncusol) have been isolated from several Juncus species, 
whereas others have a more limited distribution, and they have been isolated exclusively from one 
plant (e.g. effususins A–D from J. effusus). 
3.2.2. Chemical constituents of Juncus inflexus 
Extensive phytochemical investigations of this plant have not been reported previously. Only 
flavonoids were detected in the stem and leaf tissue of the plant. Luteolin and luteolin 7-O-glucoside, 
luteolin 5-methyl ether, luteolin 5-methyl ether 7-O-glucoside, luteolin 7-O-glucoside sulphate, 
chrysoeriol and chrysoeriol 7-O-glucoside sulphate were identified by comparing their Rf values and 
colours with standards.42 
3.2.3. Chemical constituents of Luzula luzuloides 
Earlier chemical investigations of the genus Luzula revealed the presence of several flavonoids, but 
comprehensive phytochemical investigations of the plant have not been reported previously.42,49 
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3.3. PHARMACOLOGY OF JUNCACEAE PHENANTHRENES 
Phenanthrenes isolated from different Juncaceae species exert many different activities, including 
antitumor,28-32 anti-inflammatory,23,27,29,31 antioxidant,23 anxiolytic,7,9 cell-protective,11 sedative,8,9 and 
spasmolytic32 effects. 
3.3.1. Cytotoxic and antiproliferative activity 
Several phenanthrenes isolated from Juncus species were screened for their in vitro cytotoxic activity 
in various cancer cell lines. The first example of cytotoxic Juncaceae phenanthrenes was juncusol, 
which was proved to be active against NCI 90 KB (human epidermoid nasopharynx carcinoma) cell line 
with an ED50 of 0.3 μg/mL.66 The bioactivity of several 9,10-dihydrophenanthrenes from J. effusus was 
screened by the use of brine shrimp lethality and antitumor potato disc assays.68 All of the compounds 
showed toxicity, especially the ones with vinyl or carbinol substitution at C-5, and hydroxy function in 
ring C. 2,7-Dihydroxy-1-methyl-5-aldehyde-9,10-dihydrophenanthrene and juncuenin E inhibited 
moderately the growth of MCF-7 (human breast adenocarcinoma) and HeLa (human cervix 
adenocarcinoma) cells compared to adriamycin as positive control by the use of sulforhodamine B 
assay.9,28 Among the dimers, effususin A displayed marked activity, and effususin B possessed 
noteworthy activity against SHSY-5Y (human neuroblastoma), HepG2 (human hepatocellular liver 
carcinoma), HeLa and MCF-7 cell lines compared to paclitaxel in a CCK-8 assay.29 ISHIUCHI et al. 
demonstrated the caspase-3-mediated cytotoxic activity of effusol, juncusol, juncuenin B, 
dehydrojuncuenin B and juncuenin D on HT22 (mouse hippocampal neuroblastoma) cell line, by the 
use of MTT assay and Western blot analysis.30 Fifteen phenanthrenes isolated from J. effusus were 
screened on five cancer cell lines [SHSY-5Y, SMMC-7721 (human hepatocarcinoma), HepG2, HeLa and 
MCF-7] in order to evaluate their cytotoxic activities.31 5-(1-Methoxyethyl)-1-methyl-phenanthrene-
2,7-diol showed selective and very promising inhibitory activity on MCF-7 cell line (IC50 = 10.87 μM) 
compared to paclitaxel (IC50 = 28.36 μM) in CCK-8 assay. Dehydroeffusal inhibited the growth of HepG2 
(IC50 = 12.43 μM) and HeLa (IC50 = 13.07 μM) cells two-three times more effectively than the positive 
control paclitaxel (IC50 = 36.77 μM and 25.79 μM, respectively). The results indicated that the presence 
of a hydroxy group at C-7 is necessary for cytotoxic activity. Moreover, vinyl substitution at C-5, and 
an unsaturated C-9–C-10 bond increase the effect. 
 Dehydroeffusol was isolated by antitumor activity-guided fractionation from J. effusus, after 
screening 120 traditional Chinese medicinal herbs. The compound inhibited the growth of highly 
metastatic cancer cell lines [SGC-7901 (human gastric carcinoma) and AGS (human caucasian gastric 
adenocarcinoma)] in a dose-dependent manner.32 The effective inhibition of gastric cell adhesion, 
migration, invasion and gastric cancer cell mediated vasculogenic mimicry with very low toxicity makes 
dehydroeffusol a very promising candidate for anti-gastric cancer drug development. 
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3.3.2. Antimicrobial activity 
Juncusol, isolated from J. roemerianus, showed potential antimicrobial activity against gram-positive 
bacteria, including Bacillus subtilis and Staphylococcus aureus, but gram-negative strains (e.g. 
Enterobacter aerogenes, Escherichia coli and Pseudomonas aeruginosa) were resistant towards the 
compound.32 These findings suggested that juncusol may inhibit a specific system, or a specific reaction 
found only in gram-positive microorganisms, although the mechanism of action of juncusol was not 
established. In another study, the antibacterial activity of dehydroeffusol and juncusol isolated from 
J. effusus was tested against methicillin resistant and -sensitive S. aureus. It was observed that the 
activity of the compounds increased after UVA irradiation, with 16- and two-fold, respectively.33 
3.3.3. Anti-algal activity 
Various vinyl, methyl, and hydroxy substituted 9,10-dihydrophenanthrenes isolated from J. acutus and 
J. effusus displayed significant in vitro phytotoxicity against the microalga, Selenastrum 
capricornutum.69-71 According to the results, 9,10-dihydrophenanthrenes were more active than their 
phenanthrene analogues. Dimeric dihydrophenanthrenes were also tested for their anti-algal activity, 
and they possessed more pronounced activity than the monophenanthrenes.40 The anti-algal effect of 
mono- and diphenanthrenes was decreased with the reduction of the polarity. It can be concluded, 
that the anti-algal activity of phenanthrenes can contribute to the allelochemical toxicity of Juncus 
species.81 
3.3.4. Anti-inflammatory activity 
J. effusus has been used in folk medicine as a remedy for inflammation. Therefore, phenanthrenes 
from the plant were tested for their anti-inflammatory activity by the inhibition of LPS-induced NO 
production on RAW 264.7 cells. By the use of this assay, the strong anti-inflammatory activity of 
effususin B (IC50 = 7.42 μM) was demonstrated, while other dimers from the plant [effususin A (IC50 = 
20.43 μM), effususin C (IC50 = 35.58 μM) and effususin D (IC50 = 29.14 μM)] possessed moderate activity 
compared to the positive control quercetin (IC50 = 6.63 μM).29 MA et al. isolated sixteen phenanthrenes 
from the medulla of J. effusus and evaluated their anti-inflammatory properties by the 
abovementioned assay.31 8-Hydroxymethyl-2-hydroxy-1-methyl-5-vinyl-9,10-dihydrophenanthrene 
(IC50 = 14.42 μM), 5-(1-methoxyethyl)-1-methylphenanthrene-2,7-diol (IC50 = 11.10 μM), effusol (IC50 = 
15.13 μM), dehydroeffusol (IC50 = 12.69 μM), dehydroeffusal (IC50 = 10.50 μM), 2,7-dihydroxy-5-
hydroxymethyl-1-methyl-9,10-dihydrophenathrene (IC50 = 16.06 μM), 5-hydroxymethyl-1-methyl-
phenanthrene-2,7-diol (IC50 = 16.30 μM), dehydrojuncusol (IC50 = 15.57 μM), and the mixture of 2,7-
dihydroxy-1,8-dimethyl-5-vinyl-9,10-dihydrophenanthrene and juncusol (IC50 = 13.65 μM) showed 
remarkable activities in comparison with the positive control quercetin. Effususol A (IC50 = 33.12 μM) 
and juncuenin G (IC50 = 23.63 μM) were less active, while juncuenin F (IC50 > 50 μM), 2,7-dihydroxy-1-
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methyl-5-aldehyde-9,10-dihydrophenanthrene (IC50 > 50 μM) and dehydrojuncuenin E (IC50 > 50 μM) 
were proved to be inactive. 
The anti-inflammatory property of juncutol was evaluated by the inhibition of iNOS protein 
expression in LPS-stimulated RAW 264.7 cells.23 Juncutol displayed noteworthy anti-inflammatory 
activity, the iNOS level was reduced to 11.2% from 100% after treating with 10 μM of the compound. 
Juncusol and dehydrojuncusol showed moderate activity, the expression of the protein was decreased 
to 35.0% and 59.0%, respectively. Among the studied phenanthrenes, 6-hydroxymethyl-1-methyl-5-
vinyl-9,10-dihydrophenanthrene-2-ol was the less active, the iNOS level was decreased to 82.0%. None 
of the investigated four phenanthrenes influenced the COX-2 expression. 
Dehydrojuncusol and its dimer (8,8'-bidehydrojuncusol) were also assayed by the 
abovementioned method.27 According to the immunoblot analysis, the effect of dehydrojuncusol on 
the iNOS protein (41.0% inhibition at 10 μM) decreased dramatically after dimerization (< 12.0% 
inhibition at 10 μM). 
3.3.5. Antioxidant activity 
The antioxidant capacity of dehydrojuncusol and 8,8'-bidehydrojuncusol were measured by ABTS 
radical cation decolourisation assay. The diphenanthrene inhibited effectively the free radical 
scavenging generation, comparable to the positive control ascorbic acid, and its monomer also 
possessed moderate activity.27 
In vitro cellular protective effect of dehydroeffusol was proved on human erythrocytes by the 
use of photohemolysis assay, which could be explained with the high antioxidant activity of the 
compound based on its high ROS scavenging activity.11 
3.3.6. Sedative and anxiolytic activity 
Juncus species are commonly used as sedative and anxiolytic agents in traditional Asian medicine.7-9 
The ethnopharmacological use of the plants was confirmed by the isolation of their CNS-depressing 
constituents. Dehydroeffusol was the first phenanthrene tested for its anxiolytic and sedative effects.7 
The compound increased the time spent with open arms and elevated the frequency of the entries in 
mice. The anxiolytic effect of dehydroeffusol was further confirmed with the hole-board test; 5 mg/kg 
orally administered dehydroeffusol enhanced the number of head-dips. The sedative property of the 
compound was proved by the open field test. In the rota-rod test, the phenanthrene did not increase 
the fall-down time, which indicates that the compound had no effects on the motor activity. In 
conclusion, dehydroeffusol reduced anxiety in mice, and its sedative activity was not linked with 
decreased motoric function. 
WANG et al. proved the anxiolytic properties of effusol and juncusol on mice in the elevated plus-
maze test; their sedative activity was also confirmed by the decreased locomotion in the open field 
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test.9 The mechanism of action study revealed that effusol and dehydroeffusol inhibited dose-
dependently the α1β2γ2s subtype of GABAA receptors.8 The benzodiazepine antagonist flumazenil did 
not inhibit the action of these phenanthrenes. Therefore, it was assumed that effusol and 
dehydroeffusol were not attached to the benzodiazepine binding site of GABAA receptor. 
3.3.7. Spasmolytic activity 
Phenanthrene-containing plants were used by Native Americans in order to treat stomach aches, and 
to avoid abortion. The spasmolytic effects of numerous phenanthrenes have been demonstrated, but 
only dehydroeffusol was investigated for its antispasmodic properties among Juncaceae 
phenanthrenes so far.22 Although, in high doses dehydroeffusol increased the contractions, in lower 
doses it inhibited the effects of several spasmogens (KCl, pilocarpin, histamine, Bay-K8644) on isolated 
rat jejunum.32 
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4. MATERIALS AND METHODS 
4.1. PLANT MATERIAL 
Plants [Juncus acutus L., J. alpinoarticulatus Chaix, J. articulatus L., J. compressus Jacq., 
J. conglomeratus L., J. effusus L., J. filiformis L., J. gerardii Loisel., J. inflexus L., J. maritimus Lam., 
J. monanthos Jacq., J. squarrosus L., J. tenuis Willd., J. trifidus L., Luzula campestris (L.) DC., L. forsteri 
(Sm.) DC., L. luzuloides (Lam.) Dandy & Wilmott, L. sudetica (Willd.) Schult. and L. sylvatica (Huds.) 
Gaudin] were collected during the flowering period between May and September 2014, in several 
regions of the Carpathian Basin (Hungary, Croatia and Romania). Botanical identification of the plant 
materials was performed by Gusztáv Jakab (Institute of Environmental Sciences, Szent István University, 
Szarvas, Hungary) and voucher specimens (No. 869–873) have been deposited at the Department of 
Pharmacognosy, University of Szeged, Szeged, Hungary. The plant material was dried at room 
temperature. 
4.2. PREPARATION OF PLANT EXTRACTS FOR PHYTOCHEMICAL AND PHARMACOLOGICAL SCREENING 
Extracts were prepared from 20 g of air-dried, powdered plant materials with 300 mL of MeOH with 
the use of an ultrasonic bath (3 × 15 min). After filtration, the solutions were evaporated to dryness 
under reduced pressure on a Büchi Rotavapor R-210 at 40 °C. The residues were dissolved in 50 mL of 
50% aqueous MeOH and were subjected to solvent–solvent partition between n-hexane (3 × 100 mL) 
(extracts A), CH2Cl2 (3 × 100 mL) (extracts B) and EtOAc (3 × 100 mL) (extracts C); and the remaining 
H2O extracts were named as extracts D. The fractions were concentrated and monitored by thin-layer 
chromatography (TLC), using cyclohexane–EtOAc–MeOH (20:10:1) as mobile phase. The TLC 
separations were monitored at 254 and 366 nm, and at daylight after spraying with vanillin-sulfuric 
acid reagent and heating at 120 °C for 5 min. Mobile phases in all types of chromatography methods 
are given in terms of volume ratio, v/v. 
4.3. GENERAL EXTRACTION AND ISOLATION PROCEDURES 
Open-column chromatography: OCC was performed on polyamide (MP Biomedicals 09602). 
Vacuum-liquid chromatography: For normal phase VLC, silica gel 60 G (15 μm, Merck 1.11678) was 
used. LiChroprep RP-18 (40–63 µmm, Merck 113900) stationary phase was used for reversed phase 
VLC. 
Gel filtration chromatography: Sephadex LH-20 (25–100 μm, Pharmacia Fine Chemicals) was used for 
gel filtration. 
Medium pressure liquid chromatography: MPLC was performed by a Biotage SP1TM Purification 
System using a KP-C18HS 40+M column. 
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Isocratic high-performance liquid chromatography: HPLC was carried out with a Shimadzu LC-10AT 
pump interface equipped with a Shimadzu SPD-20A UV-Vis detector using Luna® Phenyl-Hexyl column 
(250 × 10 mm, 5 µm). 
Thin-layer chromatography: Preparative thin-layer chromatography (PLC) was performed on silica 
gel 60 F254 (Merck 105715). Separation was monitored in UV light at 254 nm and 366 nm. Compounds 
were eluted from the scraped adsorbent with CH2Cl2–MeOH (4:1). The OCC, VLC, PLC, MPLC fractions 
obtained were monitored by TLC on silica gel 60 F254 (Merck 105554) and on reversed phase silica 
gel 60 F254 (Merck 105559). 
Visualization methods: UV light at 254 nm and 366 nm, and at daylight after spraying with vanillin-
sulfuric acid reagent and heating at 120 °C for 5 min. 
4.4. STRUCTURE DETERMINATION OF THE ISOLATED COMPOUNDS 
Optical rotations were determined in MeOH at room temperature with a Perkin-Elmer 341 polarimeter. 
NMR spectra were recorded in CD3OD and DMSO-d6 on a JEOL ECS 400 MHz FT-NMR at 400 MHz 
(1H) and 100 MHz (13C), with tetramethylsilane (TMS) as internal standard, and on a Bruker Avance DRX 
500 spectrometer at 500 MHz (1H) and 125 MHz (13C). Chemical shifts were referenced to TMS (1H) or 
to residual solvent resonances. Two-dimensional (2D) experiments were performed with standard 
JEOL or standard Bruker software. In the 1H–1H COSY, HSQC and HMBC experiments, gradient-
enhanced versions were applied. 
High-resolution MS data were recorded on a Waters-Micromass Q-TOF Premier mass 
spectrometer equipped with an electrospray source, and on a Thermo Scientific Q-Exactive Plus 
orbitrap mass spectrometer equipped with ESI ion source in positive ionization mode. The resolution 
was over 1 ppm. 
APCI-MS measurements were performed on an API 2000 Triple Quad mass spectrometer (AB 
SCIEX, Framingham, MA, USA) with an atmospheric pressure chemical ionization (APCI) interface, using 
positive and negative polarity. The source temperature was 350 °C and the samples were dissolved in 
CH3CN. 
4.5. ABSOLUTE CONFIGURATION DETERMINATION OF THE CHIRAL COMPOUNDS 
HPLC-ECD analysis 
Chiral HPLC separations were performed with a JASCO HPLC system using Chiralpak IA column with 
250 mm × 4.6 mm i.d., 5 m (Daicel, Chemical Industries Ltd.) and n-hexane–propan-2-ol as eluent at 
a flow rate of 1.0 mL/min). HPLC-UV and optical rotation (OR) chromatograms were recorded with 
JASCO MD-910 multiwavelength and OR-2090Plus chiral detector, respectively. The on-line ECD and 
UV spectra were measured simultaneously by stopping the flow at the UV absorption maximum of 
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each peak. The values of the ECD ellipticity () were not corrected for the concentration. Three 
consecutive scans were recorded and averaged for an HPLC-ECD spectrum with standard sensitivity, 
2 nm bandwidth and 1 s response. The background HPLC-ECD spectrum of the eluent was recorded in 
the same way. ECD spectra were recorded on a J-810 spectropolarimeter. 
Computational section 
Mixed torsional/low-frequency mode conformational searches were carried out by means of the 
Macromodel 9.9.223 software using the Merck Molecular Force Field (MMFF) with an implicit solvent 
model for CHCl3.82 Geometry reoptimizations were carried out at the B3LYP/6-31G(d) level in vacuo, 
the B97D/TZVP 83,84 and the CAM-B3LYP/TZVP 85,86 levels with the PCM solvent model for CH3CN or 
CHCl3. TDDFT ECD calculations were run with various functionals (B3LYP, BH&HLYP, CAM-B3LYP, PBE0) 
and the TZVP basis set as implemented in the Gaussian 09 package with the same or no solvent model 
as in the preceding DFT optimization step.87 ECD spectra were generated as sums of Gaussians with 
3000 cm-1 widths at half-height (corresponding to ca. 24/41 nm at 280/370 nm), using dipole-velocity-
computed rotational strength values. 88  Boltzmann distributions were estimated from the ZPVE-
corrected B3LYP/6-31G(d) energies in the gas-phase calculations and from the B97D/TZVP and CAM-
B3LYP/TZVP energies in the solvated ones. The MOLEKEL software package was used for visualization 
of the results 89-91 
4.6. HPLC-MS SCREENING METHODS 
The HPLC-MS characterization was performed using a Shimadzu liquid chromatographic system (DGU-
20A3 degasser, LC-20AD pumps, SIL-20A autosampler, CBM-20A controller, CTO-20AC column 
thermostat) coupled with API 2000 Triple Quad mass spectrometer, with turbo ESI ion source. 
Kinetex®(Phenomenex) 2.6 µm C18 column (50 × 2.1 mm, 100 Å) thermostated at 40 °C was used for 
the separation during the analysis. Mobile phase A was 0.1% formic acid in ultrapure water (R > 18.3 
MΩ) and mobile phase B was 0.1% formic acid in gradient grade acetonitrile. The separation was 
performed by gradient elution with 500 µL/min flow rate. Mobile phase B ratio had a linear gradient 
from 5% to 95% in 10 minutes. The LC flow was split to 50 µL/min with a tee-connector (split ratio was 
measured at the initial LC conditions). MS detector worked in negative MRM mode. The turbo ion 
source nebulizer was set to 28 units (arbitrary), the auxiliary or turbo gas was set to 30 units and its 
temperature was 150 °C. Data acquisition and evaluation were performed by using Analyst 1.5.1 
software. 
4.7. PHARMACOLOGICAL TESTS 
Pharmacological investigations were performed in cooperation with the Institute of Clinical 
Microbiology, University of Szeged, Szeged, Hungary; the Graduate Institute of Natural Products, 
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Chang Gung University, Taoyuan, Taiwan; the Research Center for Industry of Human Ecology and 
Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, 
Taoyuan, Taiwan; and the Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, 
Taiwan. 
4.7.1. In vitro antibacterial investigations 
Test microorganisms 
The test microorganisms were one standard and nine clinical isolates with different antibiotic resistant 
profile, originated various departments of Albert Szent-Györgyi Health Center and identified in the 
Institute of Clinical Microbiology at University of Szeged by conventional method. 
The standard strain was methicillin-resistant Staphylococcus aureus (ATCC43300). The clinical 
strains were multiresistant (MR) Acinetobacter baumannii (64060/2 and 61748/2), ESBL-positive 
Citrobacter freundii (63458), ESBL-positive Enterobacter cloacae (63033), ESBL-positive Escherichia coli 
(64663), ESBL-positive Klebsiella pneumoniae (63735), MR Pseudomonas aeruginosa (61485/1 and 
64658) and methicillin-resistant Staphylococcus aureus (64326). Microbial cultures were grown on 
standard Mueller-Hinton agar plates and maintained at 4 °C throughout the study to use as stock 
cultures. 
Antibacterial screening 
Antibacterial activities of the fractions and the pure compounds were first screened for their inhibitory 
zones by disc-diffusion method. 92  The plant extracts were prepared at 50 mg/mL, while pure 
compounds were diluted to 10 mg/mL using DMSO. The sterile filter paper discs (6 mm diameter) 
impregnated with the extracts (10 μL) were placed on the agar plate seeded with the respective 
bacterial suspension (inoculums 0.5 McFarland, 1-2 × 108 CFU/mL). The solvent was served as negative 
control. The plates were then incubated at 37 °C for 24 hours under aerobic conditions. The diameters 
of inhibition zones produced by the plant extracts and the pure compounds (including the disc) were 
measured and recorded. All experiments were carried out in triplicate. 
Determination of the MIC values 
The active compounds and the extracts with a diameter of inhibition zone ≥ 10 mm were subjected to 
determine their minimal inhibitory concentration (MICs) by the microdilution method.93 Briefly, in the 
96-well plates the stock solutions of the compounds (50 mg/mL in DMSO) were serially diluted with 
Mueller-Hinton broth to arrive at final concentration between 2.5 mg/mL and 4.9 µg/mL. 100 µL of 
inoculum (0.5 McFarland, 1-2 × 108 CFU/mL) were then added to the wells. A sterility check (medium 
and DMSO in amount corresponding to the highest concentration), negative control (medium, DMSO 
and inoculum) and positive control (medium, DMSO, inoculum and vancomycin) were included for 
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each experiment. The plates were then incubated at 37 °C for 24 hours under aerobic environment. 
The MIC of preparation was the lowest concentration that completely inhibited the visible bacterial 
growth. All experiments were performed twice in triplicate. 
4.7.2. In vitro anti-inflammatory investigations 
Preparation of human neutrophils 
Blood was taken from healthy human donors (20–30 years old) by venipuncture using a protocol 
approved by the Institutional Review Board at Chang Gung Memorial Hospital. Neutrophils were 
isolated using a standard method.94,95 Briefly, the cells were obtained from peripheral blood according 
to the standard method of dextran sedimentation, followed by centrifugation in a Ficoll-Hypaque 
gradient and the hypotonic lysis of the erythrocytes. The purified neutrophils contained > 98% viable 
cells, as determined by Trypan blue exclusion, and were suspended in calcium-free HBSS at 4 °C before 
used. 
Measurement of superoxide generation 
SOD inhibition was measured by the reduction of ferricytochrome c.94,95 Neutrophils (6 × 105 cells/mL) 
in 0.5 mg/mL ferricytochrome c and 1 mM Ca2+ were equilibrated at 37 °C for 2 min and then incubated 
with drugs for 5 min. The cells were activated using formyl-methionyl-leucyl-phenylalanine (fMLP, 
100 nM)/cytochalasin B (CB, 1 μg/mL) for 10 min. The absorbance was continuously monitored at 
550 nm using a double-beam, six-cell positioned spectrophotometer with constant stirring (Hitachi U-
3010, Tokyo, Japan). Calculations were based on the differences in absorbance with and without SOD 
(100 μg/mL) divided by the extinction coefficient for the reduction of ferricytochrome c (ε = 
21.1/mM/10 mm). 
Measurement of elastase release 
The degranulation of azurophilic granules was determined by elastase release.94,95 Neutrophils (6 × 105 
cells/mL) were equilibrated in MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide (100 μM), an elastase substrate, 
at 37 °C for 2 min and then incubated with drugs for 5 min. The cells were activated using fMLP 
(100 nM) in the presence of CB (0.5 μg/mL), and changes in the absorbance at 405 nm were 
continuously measured to monitor elastase release. The results are expressed as a percentage of 
elastase release in the fMLP/CB-activated, drug-free control system. 
Statistical methods 
Results of the anti-inflammatory assays were expressed as means ± S.E.M. Statistical analysis using 
Student’s t-test was performed with SigmaPlot (Systat Software, San Jose, CA, USA). A value of P < 0.05 
was considered statistically significant. 
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5. RESULTS 
5.1. SCREENING OF JUNCACEAE SPECIES FOR ANTIBACTERIAL ACTIVITY 
As part of our screening program for biologically active compounds in Juncaceae plants occurring in 
the Carpathian Basin, 19 species of the family were investigated for their antibacterial effects. In our 
experiments first methanol extracts were prepared from whole plants, or where it was possible from 
different plant parts (aerial part, root). After filtration and evaporation, the dry extracts were 
suspended in 50% aqueous MeOH and subjected to solvent–solvent partition with n-hexane, 
dichloromethane and EtOAc, to yield 96 fractions of different polarity. 
All fractions were tested for their antibacterial activity against 10 multiresistant bacterial strains. 
The activities of extracts were screened firstly for their inhibitory zones by disc-diffusion method at 
concentrations of 50 mg/mL. According to the screening assay, several extracts showed anti-MRSA 
activity with mild to strong effectiveness. The results of the antibacterial assays are listed in Table 1. 
Table 1. Anti-MRSA activity of plant extracts 
Plant species 
Plant 
part 
Extract 
Inhibition zone (mm) ± SD MIC 
(μg/mL) MRSA (ATCC 43300) MRSA (64326) 
J. acutus L. Wp B 10.0 ± 0.0 10.0 ± 0.0 156 
J. articulatus L. Wp B 9.3 ± 0.5 9.0 ± 0.8  
J. compressus Jacq. Wp B 9.3 ± 0.6 9.3 ± 0.6  
J. effusus L. R B 13.0 ± 0.0 13.0 ± 1.0 39  
Ap B 8.6 ± 0.6 8.6 ± 0.6  
J. filiformis L. Wp B 9.6 ± 0.6 8.6 ± 1.2  
 Wp D 7.6 ± 0.6 8.6 ± 1.2  
J. gerardii Loisel. Wp B 10.3 ± 2.0 9.0 ± 1.0 78 
J. inflexus L. R B 14.6 ± 1.2 13.0 ± 1.0 9.75 
 Ap B 8.0 ± 0.0 8.0 ± 0.0  
J. maritimus Lam. Wp B 12.3 ± 0.6 12.3 ± 0.6 78 
J. monanthos Jacq. Wp B 9.0 ± 0.8 9.0 ± 0.8  
J. squarrosus L. R B 8.0 ± 0.0 8.3 ± 0.6  
 Ap B 8.6 ± 0.6 8.3 ± 0.6  
J. tenuis Willd. R B 8.3 ± 0.6 8.6 ± 0.6  
 Ap B 10.3 ± 0.6 9.6 ± 0.6 156 
L. campestris (L.) DC. Wp B 6.7 ± 0.6 6.7 ± 0.6  
L. forsteri (Sm.) DC. Wp B 7.3 ± 0.6 7.3 ± 0.6  
L. sylvatica (Huds.) Gaudin Ap B 6.7 ± 0.6 6.7 ± 0.6  
Vancomycin*   15.5 ± 0.6 15.5 ± 0.6  
Data represents the mean value of clear inhibition zone (diameter of inhibition zone plus diameter of the disc) obtained from 
three independent experiments. As well as the minimal inhibitory concentration (MICs) of the extracts with diameter of 
inhibition zone ≥ 10 mm by the microdilution method. The extracts without any antibacterial activity were not presented in 
the table. Abbreviations: Ap = Aerial part; R = Root; Wp = Whole plant; B = CH2Cl2 fraction; D = remaining H2O fraction. 
*Vancomycin was used as positive control at 5 µg/disc. 
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16 Fractions (CH2Cl2 and remaining H2O) from Juncus species and 3 CH2Cl2-soluble fractions from 
Luzula species possessed mild to strong inhibitory activities against MRSA strains (inhibition zones = 
6.7 mm – 14.6 mm; Table 1). 
A total of 6 extracts had diameters of inhibition zone ≥ 10 mm, therefore these were studied 
further to determine their minimal inhibitory concentrations (MICs) by the microdilution method. The 
most active fractions were exclusively fractions B (containing CH2Cl2-soluble lipophilic constituents). 
Among them, the CH2Cl2-soluble fraction of the roots of J. inflexus showed the highest activity (MIC = 
9.75 μg/mL). Fraction B of the roots of J. effusus displayed significant anti-MRSA activity (MIC = 39 
μg/mL). The CH2Cl2-soluble fraction of J. maritimus and J. gerardii possessed marked activity (MIC = 78 
μg/mL, for both extracts), and mild anti-MRSA activities were observed for fraction B of J. acutus 
(whole plant) and for fraction B prepared from the aerial parts of J. tenuis (MIC = 156 μg/mL, for both 
extracts). The antibacterial activity of the species belonging to the genus Juncus was more significant 
(inhibition zones = 7.6 mm – 14.6 mm) than the activity of the species of genus Luzula (inhibition zones 
= 6.7 mm – 7.3 mm). 
5.2. ANTI-INFLAMMATORY ACTIVITY OF LUZULA SPECIES 
The anti-inflammatory activity of 24 extracts [n-hexane (A), CH2Cl2 (B), EtOAc (C) and remaining H2O 
(D)] prepared from five species (L. campestris, L. forsteri, L. luzuloides, L. sudetica and L. sylvatica) 
were tested (Table 2). 
The apolar n-hexane-soluble fractions of L. forsteri, L. luzuloides, L. sudetica and L. sylvatica 
showed higher than 70% inhibition at the tested concentration (10 μg/mL) in both assays. The fraction 
A of L. campestris exerted the most selective elastase release inhibition. Among the fractions with 
different polarities, fractions B (containing CH2Cl2-soluble lipophilic constituents) had the most 
remarkable activities (> 93% inhibition) at a concentration of 10 μg/mL. All of the CH2Cl2-soluble 
fractions displayed high activities on the inhibition of elastase release, and proved to be slightly less 
active on superoxide generation. The EtOAc-soluble fractions of L. campestris, L. luzuloides, L. sudetica 
and L. sylvatica (aerial part) possessed noteworthy (> 65%) inhibitory activities at 10 μg/mL. The 
remaining H2O fraction of L. luzuloides also showed notable anti-inflammatory activities (> 65%) in 
both methods. 
Regarding to the species, L. luzuloides was the most promising; all fractions of the plant showed 
mild to strong inhibitory activities in both assays, although the effects of the fractions were slightly 
more pronounced on the elastase release. On the basis of the results of the preliminary screening, the 
lipophilic extract of L. luzuloides was selected for more detailed phytochemical studies, with the aim 
of the identification of their anti-inflammatory constituents. 
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Table 2. Inhibitory effects of extracts with different polarity from Luzula species on superoxide anion generation 
and elastase release on human neutrophils in response to fMLP/CB 
Plant species Extract 
Superoxide anion 
inhibition (%) 
Elastase inhibition 
(%) 
Luzula campestris (L.) DC. 
A 50.04 ± 5.08*** 106.98 ± 6.35*** 
B 96.06 ± 0.91*** 112.19 ± 6.16*** 
C 77.45 ± 6.44*** 84.22 ± 4.09*** 
D 32.52 ± 5.43*** 45.18 ± 6.47*** 
L. forsteri (Sm.) DC. 
A 71.53 ± 7.75*** 71.88 ± 7.07*** 
B 93.14 ± 6.14*** 113.51 ± 1.07*** 
C 35.24 ± 1.43*** 37.95 ± 6.88** 
D 32.80 ± 3.40*** 54.52 ± 0.99*** 
L. luzuloides (Lam.) 
A 70.65 ± 6.65*** 92.50 ± 3.58*** 
B 99.39 ± 0.37*** 114.22 ± 3.13*** 
C 62.84 ± 3.50*** 68.39 ± 5.74*** 
D 68.80 ± 5.92*** 77.71 ± 4.99*** 
L. sudetica (Willd.) Schult. 
A 72.85 ± 6.35*** 76.08 ± 5.45*** 
B 109.25 ± 6.01*** 115.21 ± 4.14*** 
C 77.95 ± 0.22*** 91.41 ± 1.84*** 
D 37.92 ± 5.39** 8.59 ± 3.19 
L. sylvatica (Huds.) Gaudin 
(aerial part) 
A 85.27 ± 4.20*** 89.10 ± 6.41*** 
B 96.09 ± 1.92*** 111.90 ± 2.99*** 
C 73.32 ± 2.91*** 54.82 ± 4.11*** 
D 26.90 ± 7.01** 48.83 ± 6.51** 
L. sylvatica (Huds.) Gaudin 
(root part) 
A 89.18 ± 6.58*** 107.88 ± 3.96*** 
B 95.28 ± 2.48*** 104.23 ± 5.67*** 
C 53.62 ± 7.13*** 54.13 ± 3.03*** 
D 41.60 ± 6.19*** 43.02 ± 2.96*** 
A = n-hexane soluble fraction; B = CH2Cl2 fraction; C = EtOAc fraction; D = remaining H2O fraction 
Results are presented as mean ± S.E.M. (n=3–5). ** P < 0.01, *** P < 0.001 compared with the control value (DMSO). 
5.3.  ISOLATION AND PURIFICATION OF COMPOUNDS FROM JUNCUS INFLEXUS 
The air dried roots of J. inflexus (3.5 kg) were grounded with a Retsch mill (model SM 100 comfort), 
and percolated with MeOH (60 L) at room temperature. The crude extract (393 g) was concentrated in 
vacuo. The extract was dissolved in 500 mL 50% MeOH, and liquid-liquid partition was performed with 
n-hexane (5 × 700 mL), then with CH2Cl2 (5 × 1000 mL), and finally with EtOAc (5 × 1000 mL). 
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The CH2Cl2 fraction (52.8 g) was chromatographed on a polyamide column (OCC) (sorbent: 540 g, 
column: 150 mm × 350 mm) with mixtures of MeOH and H2O [2:3, 1:1, 3:2, 4:1, 1:0 (2.5, 5, 10, 40, and 
5 L, respectively); fractions were collected according to the eluents]. The fractions were concentrated 
and monitored by thin-layer chromatography (TLC) using cyclohexane–EtOAc–EtOH (20:10:1) as 
solvent system. According to their TLC chromatograms the compositions of the fractions obtained from 
the polyamide column with methanol–water 3:2 and 4:1 were similar, therefore these fractions were 
combined (J3). 
All of the fractions (J1–4) obtained from the polyamide column were subjected to antibacterial 
screening, among them J3 showed the strongest inhibitory activity against two MRSA strains 
(ATCC43300 and 64326) (inhibition zones = 15.3 ± 0.6 mm and 14.3 ± 0.6 mm, respectively), while J2 
(inhibition zones = 7.3 ± 0.6 mm, for both strains) and J4 (inhibition zones = 7.6 ± 0.6 mm, for both 
strains) possessed moderate activity, and J1 was proved to be inactive. 
Fraction J3 (32.9 g) was further chromatographed by NP-VLC (sorbent: 250 g, column: 
35 mm × 210 mm) with a gradient system of cyclohexane–EtOAc–EtOH [from 19:1:0 to 5:5:1 
(1000 mL/eluent), and finally with EtOH (1500 mL); volume of collected fractions was 100 mL] to yield 
major fractions J3/1–14, according to their TLC patterns (Figure 2). 
From fraction J3/3 (35.9 mg) JIN-2 (16.2 mg) was crystallized. Fraction J3/4 (71.8 mg) was 
purified on Sephadex LH 20 column using MeOH as eluent [(120 mL); volume of collected fractions was 
3 mL] to afford JIN-1 (21.6 mg). JIN-4 (35.5 mg) and JIN-5 (12.2 mg) were purified from fraction J3/6 
(60.2 mg) by NP-PLC using cyclohexane–EtOAc (7:3) as solvent system. 
NP-VLC was used for the purification of fraction J3/7 (3.6 g), which was eluted with a gradient 
system of n-hexane–CH2Cl2–MeOH [from 3:7:0 to 0:97:3 (500 mL/eluent), and finally MeOH (500 mL); 
volume of collected fractions was 100 mL] to yield six subfractions. Subfraction J3/7/3 (667.7 mg) was 
further separated by NP-VLC using the gradient system of CHCl3–acetone [from 99:1 to 4:1 
(200 mL/eluent), and finally acetone (200 mL); volume of collected fractions was 20 mL] to yield six 
subfractions. Furthermore, subfraction J3/7/3/3 (84 mg) was purified by RP-VLC using a MeOH–H2O 
gradient elution [from 3:2 to 17:3 (150 mL/eluent), and finally MeOH (150 mL); volume of collected 
fractions was 12 mL] to yield six subfractions. Subfraction J3/7/3/3/4 (12 mg) was purified on Sephadex 
LH-20 column, using MeOH–CH2Cl2 (1:1) as eluent [(90 mL); volume of collected fractions was 2 mL] to 
afford JIN-19 (4.1 mg). Furthermore, from J3/7/4 JIN-3 (850 mg) was crystallized. Subfraction J3/7/5 
(324 mg) was separated on Sephadex LH-20 column, using MeOH as eluent [(80 mL); volume of 
collected fractions was 2 mL] to afford JIN-7 (52.1 mg). 
Fraction J3/11 (370.2 mg) was subjected to RP-MPLC using a gradient system of MeOH–H2O 
[from 1:1 to 4:1, and finally with MeOH (300 mL each), at a flow rate of 6 mL/min; volume of collected 
fractions was 9 mL] to yield 12 subfractions. JIN-15 (7.5 mg) was obtained from fraction J3/11/4 
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(11.0 mg) after using NP-PLC with CH2Cl2–MeOH (19:1) as a solvent system. Subfraction J3/11/8 
(23.3 mg) was chromatographed by gel filtration using MeOH as mobile phase [(100 mL); volume of 
collected fractions was 3 mL] to get JIN-12 (6.7 mg) and JIN-13. Final purification of JIN-13 (5.2 mg) 
was performed by RP-HPLC, eluted with MeOH–H2O (7:3) at a flow rate of 2 mL/min (tR = 21.5 min). 
Subfraction J3/11/10 (25.2 mg) was further chromatographed on Sephadex LH-20 column using the 
mobile phase MeOH [(200 mL); volume of collected fractions was 4 mL] to get JIN-11 (3.8 mg). 
Fraction J3/12 (405.1 mg) was further separated by RP-VLC by a gradient system of MeOH–H2O 
[from 3:7 to 9:1 (100 mL/eluent), and finally MeOH (200 mL); volume of collected fractions was 15 mL] 
to yield 10 subfractions. From subfraction 4 JIN-8 (6.1 mg) was isolated by the use of NP-PLC, using 
CH2Cl2–MeOH (19:1) as solvent system. 
 
Figure 2. Isolation of compounds from J. inflexus 
5.4.  ISOLATION AND PURIFICATION OF COMPOUNDS FROM LUZULA LUZULOIDES 
The air-dried whole plant of L. luzuloides (480 g) was powdered with a Retsch mill (model SM 100 
comfort), and percolated with MeOH (20 L) at room temperature. The crude extract was concentrated 
(40 mL) in vacuo. The extract (76 g) was suspended in 200 mL of 50% MeOH and subjected to solvent–
solvent partitioning with CH2Cl2 (5 × 500 mL). 
After evaporation, the CH2Cl2 fraction (4.9 g) was chromatographed on a polyamide column 
(sorbent: 55 g, column: 45 mm × 200 mm) with mixtures of MeOH and H2O [1:1, 4:1 (1 and 4 L, 
respectively); each eluent was collected as a fraction]. The fraction obtained from the polyamide 
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column with MeOH–H2O 4:1 (1.1 g) was further chromatographed by NP-VLC (sorbent: 40 g, column: 
35 mm × 150 mm) with a gradient system of cyclohexane–EtOAc–EtOH [from 9:1:0 to 5:5:1 
(300 mL/eluent), and finally with EtOH (200 mL); volume of collected fractions was 20 mL] to yield 
twelve major fractions (L2/1–12) (Figure 3). The fractions were concentrated and monitored by TLC 
using cyclohexane–EtOAc–EtOH (20:10:1) as solvent system. 
From fraction L2/1 (9.2 mg) LUB-1 (5.2 mg) was crystallized. Fraction L2/4 (31.3 mg) was purified 
by gel filtration using MeOH as eluent [(100 mL); volume of collected fractions was 2 mL] to afford four 
subfractions. LUB-3 (3.0 mg) was purified from subfraction L2/4/1 (10.6 mg) by NP-PLC using n-
hexane–EtOAc (7:3) as solvent system. Subfraction L2/4/3 (14.1 mg) was also purified by NP-PLC, with 
cyclohexane–EtOAc–MeOH (20:10:1) as solvent system to afford LUB-4 (5.1 mg). LUB-6 (3.2 mg) was 
crystallized from subfraction L2/4/4 (8.1 mg). 
 
Figure 3. Isolation of compounds from L. luzuloides 
Fraction L2/6 (25.1 mg) was separated by RP-VLC, with a gradient system of MeOH–H2O [from 
2:3 to 9:1 (150 mL/eluent), and finally MeOH (100 mL); volume of collected fractions was 10 mL] to 
yield five subfractions (L2/6/1–5). LUB-9 (9.0 mg) was crystallized from subfraction L2/6/2 (12.4 mg). 
Furthermore, LUB-10 (7.1 mg) was crystallized from fraction L2/7 (18.1 mg). 
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5.5. CHARACTERIZATION AND STRUCTURE DETERMINATION OF THE ISOLATED COMPOUNDS 
The structure elucidation of the compounds was performed by means of MS and NMR measurements. 
HRESIMS measurements revealed the molecular masses and molecular compositions of the novel 
compounds. Information from 1D (1H NMR and JMOD) and 2D (1H–1H COSY, NOESY, HSQC and HMBC) 
NMR experiments proved to be the most valuable for the structure determination. 
5.5.1. Compounds from Juncus inflexus 
From the CH2Cl2 fraction of J. inflexus 12 compounds (1–12) were isolated with the combination of 
different chromatographic techniques. 
JIN-7 (1) was isolated as an amorphous powder with []26 D  0 (c 0.1, MeOH). Its HRESIMS provided 
the molecular formula, C19H22O3, through the presence of a peak at m/z 321.1532 [M+Na]+ (calcd. for 
C19H22O3Na, 321.1461). The 1H NMR spectrum (Annex II) displayed signals of two ortho-coupled 
aromatic protons (δH 6.70 d and 6.84 d), and one aromatic proton as a singlet (δH 6.86), three methyls, 
two methylenes, one sp3 methine, and signals of protons belonging to one methoxy and two hydroxy 
groups. In the JMOD spectrum, the presence of 19 carbon signals was detected. In the 1H NMR 
spectrum, two methylene signals at δH 2.32 and 2.75 (2  2H) indicated this compound to be a 9,10-
dihydrophenanthrene derivative. In the 1H–1H COSY spectrum, correlations were observed between 
the H-9, H-10 methylenes, and δH 6.70 d and 6.84 d (H-3/H-4), and δH 4.69 d and 1.47 d (3H) (H-12/H-
13). The methyl doublet at δH 1.47 and a methine proton at δH 4.69 provided evidence for the presence 
of an isolated CH3CH structural unit (C-12, C-13) in the molecule. According to the 1H and 13C NMR 
signals at δH 2.85 and δC 55.0, a methoxy group could be identified, which was connected to C-12 as 
confirmed by HMBC correlation between OCH3 (δH 2.85) and C-12 (δC 74.5) (Figure 4). Moreover, on 
the basis of HMBC correlations between C-5/H3-13, C-6/H-12, and C-5a/H-12, this side chain was 
placed at C-5. One of the methyl groups (δH 2.13 s) was placed at C-1 on the basis of its HMBC 
correlation with the quaternary carbons at δC 138.8 (C-1a), 120.2 (C-1) and 153.7 (C-2), and the other 
methyl group was assigned at C-8 on the basis of the correlations of H3-14/C-8. The hydroxy groups 
linked to C-7 and C-2 were confirmed by the chemical shift of the quaternary carbons (δC-7 153.8 and 
δC-2 153.7). 
 
Figure 4. Diagnostic COSY (▬) and HMBC correlations (H→C) for 1 
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NOESY correlations confirmed the substitution pattern of compound 1. Nuclear Overhauser 
effects were detected between H-3/H-4, H-4/H-12, H-4/H-13, H3-OMe/H-12, H3-13/H-12, H-6/H3-13 
and H-9/H3-14, H-9/H-10. All of the above evidence confirmed the planar structure of 1 as 2,7-
dihydroxy-1,8-dimethyl-5-(1-methoxyethyl)-9,10-dihydrophenanthrene, which has been named as 
jinflexin A. 
The zero specific rotation and baseline ECD spectrum of jinflexin A (1) suggested it to be a 
racemic mixture, which was also confirmed by the separation of its enantiomers on a Chiralpak IA 
column using n-hexane–propan-2-ol (9:1) as eluent. The HPLC-ECD spectra of the separated 
enantiomers were recorded, which enabled the determination of absolute configuration by exploiting 
the solution TDDFT-ECD protocol.86, 96  In a preliminary MMFF conformational search of (S)-1, 31 
conformers were generated, which were then reoptimized at both the B3LYP/6-31G(d) in vacuo and 
B97D/TZVP 83,84 PCM/CHCl3 levels, resulting in five and six low-energy conformers above a 2% 
Boltzmann population, respectively. Jinflexin A (1) has an inherently chiral substituted biphenyl 
chromophore, of which the conformational freedom is restricted by an ethylidene linker. Similar to 
atropisomeric biphenyls, the populations of the preferred P- or M-helicity conformers determines the 
features of the ECD spectra, which, in turn, are governed by the absolute configuration of the benzylic 
chirality center. According to literature data of substituted 9,10-dihydrophenanthrene derivatives with 
ortho tetrasubstituted biphenyl moiety, P- and M-helicity conformers can be interconverted at 
ambient temperature by flipping the C-9 and C-10.97,98 The conformational analysis identified confor-
mers with both P- and M-helicity of the biphenyl moiety, which showed near mirror-image computed 
ECD curves. The lowest-energy B3LYP/6-31G(d) in vacuo conformer (conf. A, 63.5%) of (S)-1 had P-
helicity with 30.78° C1a,C4a,C5a,C8a torsional angle (in Appendix I), and the C-12H-12 bond of the 
benzylic chirality center was near coplanar with the benzene ring (12H,C12,C5,C5a = 12.18°). The computed 
ECD spectra of this conformer reproduced well the experimental HPLC-ECD curve of the first-eluting 
enantiomer and conformers B (12.0%) and D (5.3%) differing only in the orientation of the OH-2 and 
OH-5 protons, showed near congruent computed ECDs. In contrast, conformers C (8.6%) and E (3.3%), 
having M-helicity with 32.78° and 31.20° C1a,C4a,C5a,C8a torsional angles, respectively, showed mirror-
image computed ECD curves of the experimental ECD (in Appendix I). Thus, the proper estimation of 
the population for the P- and M-helicity conformers is fundamental for the unambiguous assignment 
of the absolute configuration.91 It was found that the distance of the H-4 and H-13 protons is 2.13 Å in 
the three P-helicity conformers (A, B and D), while this distance is larger than 4.10 Å for the M-helicity 
conformers (C and E). Since NOE correlation could be observed between H-4 and H-13 protons and 
there was no correlation between H-4 and H-15, which would be expected from conformers C and E, 
the P-helicity conformers were also confirmed experimentally as the dominant ones in solution. The 
B97D/TZVP (PCM/CHCl3) method showed an even smaller contribution of the M-helicity forms with a 
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total population of 4.5% from two conformers (in Appendix I). The ECD spectra of (S)-1 computed at 
B3LYP/TZVP, BH&HLYP/TZVP and PBE0/TZVP levels reproduced the experimental HPLC-ECD spectrum 
of the first-eluting enantiomer and thus the (S) absolute configuration could be assigned to the 
enantiomer with a negative Cotton effect (CE) at 275 nm. 
  
(±)-1 2 
JIN-12 (2) was obtained as an amorphous solid; it gave a molecular formula C19H20O3 as 
determined by HRESIMS, through the presence of a peak at m/z 297.1392 [M+H]+ (calcd. for C19H21O3, 
297.1380). The 1H and 13C NMR spectra (Annex II) suggested a 9,10-dihydrophenanthrene skeleton 
with vinyl substitution, similar to that of juncusol (7), isolated previously from other Juncus species 
(J. acutus, J. effusus and J. roemerianus).66 The differences found were that a hydroxymethyl group 
instead of the methyl group is linked to the skeleton at position C-1, and methoxy group (δH 3.84, δC 
56.1) could be placed at C-2 according to its HMBC correlation with C-2 (δC 157.4). The position of the 
hydroxymethyl group was determined by the HMBC cross-peaks between methylene protons (H-11) 
and C-1, C-1a and C-2. Nuclear Overhauser effects were observed between OCH3-2/H-3, H-3/H-4, H-
12/H3-14, H2-13/H3-14, H-8/H-9 and H-10/H2-11. All this evidence confirmed the structure of 2 (jinflexin 
B) as 7-hydroxy-6-methyl-1-hydroxymethyl-2-methoxy-5-vinyl-9,10-dihydrophenanthrene. 
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JIN-15 (3) was isolated as an amorphous yellow powder with []26 D  –19 (c 0.2, MeOH). Its 
HRESIMS provided a molecular formula of C18H20O3 through the presence of a peak at m/z 285.1498 
[M+H]+ (calcd. for C18H21O3, 285.1485). The 1H and 13C NMR chemical shifts at δH 2.24, 2.65, 2.57 and 
2.84 and δC 21.1 and 25.1 (C-9, C-10) confirmed a dihydrophenanthrene structure of 3. The 1H NMR 
spectrum exhibited two methyl singlets at δH 1.32 and 2.15, two ortho-coupled aromatic protons at δH 
7.23 (J = 8.6 Hz) and 6.71 (J = 8.5 Hz), and a vinylic system at δH 5.13, 4.90 and 6.10 (C-12, C-13) 
29 
(Annex III). The 1H–1H COSY correlations of the protons at δH 2.72, 2.98 and 3.88, and the chemical 
shifts of their carbons (δC 33.6 and 74.4) indicated a –CH2-CH(OH)– unit (–C-5–C-6–) in the molecule. 
This structural part was found to form a keto-substituted six-membered ring together with quaternary 
carbons at δC 149.4, 128.8 and 55.5, according to the long-range correlations between H-5 and C-7, C-
4a, C-8a, C-5a; H-6 and C-12, C-14; and H-12/C-8. The methyl and vinyl substitution at C-7 was indicated 
by the HMBC cross-peaks between H2-13/C-12 and C-7 as well as H3-14 and C-6, C-7, C-8, C-12, 
respectively. In the HSQC spectrum the protons of the methyl group at δH 2.15 (H3-11) were correlated 
to the carbon at δC 11.4 (C-11), and had HMBC correlations with C-1, C-1a and C-2. There was a hydroxy 
group at position C-2, which was suggested by the HMBC correlations between C-2 (δC 159.4)/H-3 and 
H-4. All the above evidence confirmed the planar structure of jinflexin C (3). The (6S*,7S*) relative 
configuration of 3 was determined on the basis of NOE correlations observed between α-oriented H-5 
(δH 2.98 m) and H-6, and β-oriented H-5 (δH 2.72 m) and H-12. 
In contrast to jinflexin A (1), jinflexin C (3) was found to be optically active with a negative specific 
rotation, and a distinct ECD spectrum could be recorded as well (in Appendix I). In order to check on 
the possibility of partial racemization, chiral HPLC analysis of 3 was carried out under the same 
conditions used for jinflexin A (1) (Chiralpack IA, n-hexane–propan-2-ol 9:1), which showed 80% 
enantiomeric excess. HPLC-ECD measurements and HPLC-ECD traces confirmed the enantiomeric 
relationship of the separated components. For the determination of the absolute configuration, the 
same ECD calculation protocol was carried out as for jinflexin A (1). The initial MMFF conformational 
search of the arbitrarily chosen (6S,7S) enantiomer yielded 96 conformers, which were reoptimized at 
the B3LYP/6-31G(d) level in vacuo and the B97D/TZVP PCM/CH3CN levels resulting in ten and 12 
conformers above 2%, respectively. In the lowest-energy B3LYP/6-31G(d) conformer, the C-7 vinyl 
group adopted an axial orientation, while OH-6 has an equatorial orientation. This conformation of 
ring C was represented by seven other computed conformers totalling 71.1% at the population, and 
an equatorial C-7 vinyl group was found in conformers C and J with a total population of 10.1%. The 
structures of the low-energy conformers were in agreement with the observed NOE correlations of 
jinflexin C (3). The ECD spectra of (6S,7S)-3 computed for the gas-phase or solvent model conformers 
gave mirror-image agreement of the experimental ECD recorded in acetonitrile allowing for the 
assignment of the absolute configuration for the major enantiomer (second-eluting enantiomer in the 
chiral HPLC analysis) of jinflexin C (3) as (6R,7R). 
JIN-19 (4) was isolated as an amorphous solid with []26 D  0 (c 0.1, MeOH). The HRESIMS (m/z 
513.2448 [M+H]+) established a molecular formula C36H32O3 (calcd. for C36H33O3 513.2424), suggesting 
the dimeric nature of compound 4. In the JMOD spectrum the presence of 36 signals was detected 
(Annex IV). The 1H NMR spectrum showed the sharp singlets for the H-11, H-11′, H-14 and H-14′ 
methyls, the doublets for H-3, H-4, H-9, H-10, H-3′ and H-4′, the aromatic singlets for the H-5 and H-8 
30 
protons, and signals for H-12′ and H-13′ (Annex IV). According to the NMR data, one of the monomers 
is a tetrasubstituted phenanthrene containing two methyls and one hydroxy groups and a 
trisubstituted carbon, while the other part of the molecule is a dihydrophenanthrene substituted with 
two methyls and two hydroxy groups. The linkage between these units was determined on the basis 
of 1H–1H COSY and HMBC experiments (Figure 5). 
 
Figure 5. HMBC spectrum, 1H–1H COSY (▬) and HMBC (H→C) correlations of jinflexin D (4) 
The 1H–1H COSY spectrum defined the structural fragment –CHCH2–CH=CH– with the relevant 
correlated protons (H-12-H-13-H-13′-H-12′). The H-12 proton was correlated in the HMBC spectrum 
with C-5, C-5′, C-6, C-6′, C-7, C-7′, and C-13′. The long-range correlations of the H3-13 protons with the 
C-6, C-6′, C-12, C-12′ and C-13′ carbons also indicated linkages to occur between C-12/C-6′ and C-13/C-
13′ of the units, forming a new ring system containing a tri- and a tetracyclic unit. Most probably, 
during the biosynthesis process, two vinyl substituted phenanthrene monomers were connected 
through their vinyl groups producing a new ring. The HMBC long-range correlations observed between 
H3-11/C-1, C-1a and C-2, and H3-14/C-8, C-8a and C-7, and H3-11′/C-1′, C-1a′ and C-2′, and H3-14′/C-8′, 
C-8a′ and C-7′ indicated the C-1, C7, C-1′ and C-7′ positions of methyl groups and the C-2, C-2′ and C-7′ 
positions of hydroxy groups, respectively. 
The NOESY correlations between H-3/H-4, H-4/H-5, H-8/H3-14, H-9/H-10, H-10/H3-11, H3-14/H-
12 and H-13, H-13/H-13′, H-12′/H-13′, H-4′/H-12′, H-11′/H-10′, H-9′/H-10′ and H-9′/H3-14′ further 
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confirmed the proposed structure of the molecule. On the basis of the above findings, the structure of 
this compound (jinflexin D) was established as depicted in structural formula 4. 
Although a distinct ECD spectrum for jinflexin D (4) could be recorded in acetonitrile, the chiral 
HPLC analysis showed only 9% enantiomeric excess and the HPLC-ECD spectra of the separated 
enantiomers were also recorded. DFT reoptimization of the initial 40 MMFF conformers generated for 
the arbitrarily chosen (R)-4 yielded nine and nine low-energy conformers (≥ 2%) at B3LYP/6-31G(d) in 
vacuo and B97D/TZVP PCM/CHCl3 levels, respectively. The B97D/TZVP PCM/CHCl3 conformers differed 
only in the orientation of the OH protons, while the relative arrangement of the fused tricyclic and 
tetracyclic units was near identical (in Appendix I). The ECD spectra of (R)-4 computed for the 
B97D/TZVP PCM/CHCl3 conformers and the Boltzmann-weighted ECD curve reproduced well the HPLC-
ECD spectrum of the second-eluting enantiomer of jinflexin D (4) and it was a mirror image of the 
experimental solution ECD spectrum. Thus, the absolute configuration of the first-eluting enantiomer 
of jinflexin D (4) was determined unambiguously determined as (R), with the enantiomeric excess 
derived from the (S) enantiomer (second-eluting enantiomer). 
 Besides the new compounds (1–4), dehydrojuncuenin A [JIN-1 (9)], juncuenin A [JIN-2 (5)], 
juncuenin B [JIN-3 (6)], dehydrojuncusol [JIN-4 (10)], juncusol [JIN-5 (7)], dehydrojuncuenin B [JIN-11 
(11)], juncuenin D [JIN-13 (8)] and chrysoeriol [JIN-8 (12)] were also isolated from the roots of 
J. inflexus (Annex I). Their structures were determined by comparison of their APCI-MS and 1H and 13C 
NMR data with those published in the literature.25,99-101 In the case of jucuenin B (6), juncusol (7), 
juncuenin D (8), dehydrojuncusol (10), and dehydrojuncuenin B (11) the previously published NMR 
data were completed with 1H and 13C NMR data determined in methanol or dimethyl sulfoxide (in 
Appendix I). 
   
 R1 R2 R3 R4 R1 R2  R3 R4 
5 H CH=CH2 CH3 H 9 H CH=CH2 CH3 H 
6 H OH CH3 CH=CH2 10 CH=CH2  CH3 OH H 
7 CH=CH2 CH3 OH H 11 H  OH CH3        CH=CH2 
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Although juncuenin D (8) is a chiral derivative, it had been isolated previously as a racemic 
mixture and thus characterization of its enantiomers has not been reported yet.25 The chiral HPLC 
analysis of juncuenin D (8) showed 4% enantiomeric excess, which however was not sufficient to 
record an acceptable solution ECD spectrum. Thus, the HPLC-ECD spectra of the separated 
enantiomers were recorded and ECD calculations were performed to assign the absolute configuration. 
The 13 initial MMFF conformers of the arbitrarily chosen (S)-8 were reoptimized at B3LYP/6-31G(d) in 
vacuo and B97D/TZVP PCM/CHCl3 levels resulting in six and nine low-energy conformers above 2%, 
respectively. Two groups of the low-energy B3LYP/6-31G(d) in vacuo conformers could be 
distinguished based on the relative orientation of the vinyl group. Conformers of the two groups had 
substantially different computed ECD curves as represented by conformers A and B. The Boltzmann-
weighted ECD spectra of the B3LYP/6-31G(d) in vacuo conformers of (S)-8 reproduced well the HPLC-
ECD spectrum of the second-eluting enantiomer of juncuenin D (8), allowing the determination of 
absolute configuration for the separated enantiomers (in Appendix I). 
5.5.2. Compounds from Luzula luzuloides 
From the CH2Cl2 extract of L. luzuloides six compounds [LUB-1 (7), LUB-3 (13), LUB-4 (6), LUB-6 (11), 
LUB-9 (14) and LUB-10 (15)] were isolated with the combination of different chromatographic 
techniques. 
LUB-3 (13) was obtained as an amorphous solid with []26 D  0 (c 0.1, MeOH). Its HRESIMS provided 
the molecular formula C18H16O3 through the presence of a peak at m/z 281.1175 [M+H]+ (calcd. for 
C18H17O3, 281.1172). The 1H NMR spectrum (Annex III) displayed signals of two pairs of ortho-coupled 
aromatic protons (δH 6.25 d/8.35 d and δH 8.12 d/7.63 d), and one aromatic proton as a singlet (δH 
7.52), two methyl singlets at δH 1.53 and δH 2.35, and a vinylic system at δH 5.81, 5.35 and 7.05 (C-14, 
C-13). In the JMOD spectrum, the presence of 18 carbon signals was detected (Annex III). In the 1H 
NMR spectrum the presence of ortho-coupled aromatic protons at δH 8.12 d and 7.63 d could be 
assigned to the H-9 and H-10 protons of a phenanthrene derivative. In the 1H–1H COSY spectrum four 
correlations were observed between δH 8.12 d and 7.63 d (H-9/H-10), between δH 6.25 d and 8.35 d 
(H-3/H-4), between δH 7.05 dd and 5.81 d (H-13/H-14a), and between δH 7.05 dd and 5.35 d (H-13/H-
14b). The two ortho-coupled doublets at δH 6.25 and 8.35 were assigned to the H-3 and H-4 protons. 
According to the 13C NMR signals at δC 207.1 one carbonyl group was identified, which was placed to 
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C-2 as confirmed by HMBC correlations of the H3-11 (δH 1.53) and H-4 (δH 8.35 d) with C-2 (δC 207.1) 
(Annex III). The location of one of the methyl groups (δH 1.53 s) was confirmed at C-1 on the basis of 
its HMBC correlation with the quaternary carbons δC 146.6 (C-1a), 78.1 (C-1) and 207.1 (C-2) (Figure 6). 
The linkage of hydroxy groups to C-1 and C-6 was confirmed by the chemical shifts of the quaternary 
carbons at δC-1 78.1 and δC-6 157.0, respectively. In the HMBC spectrum another methyl group was 
assigned at C-7 by the correlation of H3-12/C-7. The vinyl substitution at C-8 was indicated by the HMBC 
cross-peaks between H-14a/C-8 and H-14b/C-8. 
 
Figure 6. Diagnostic COSY (▬) and HMBC correlations (H→C) for 13 
The NOESY correlations further confirmed the structure of compound 13. Overhauser effects 
were detected between H-3/H-4, H-4/H-5, H-9/H-10, H-9/H-13, H-9/H-14b, H-13/H3-12, H-14b/H3-12. 
All of the above evidence confirmed the planar structure of 13 named as luzulin A. 
Luzulin A (13) is a chiral natural product but it had a very weak ECD spectrum in acetonitrile and 
zero specific rotation, which suggested that it had low enantiomeric excess. Thus chiral HPLC analysis 
of luzulin A (13) was carried out, which resulted in the separation of the two enantiomers on a 
Chiralpak IA column and determined the enantiomeric excess as 25%. 
In order to elucidate the absolute configuration of the enantiomers and identify the major 
enantiomer, HPLC-ECD spectra of the separated enantiomers were recorded and the solution TDDFT-
ECD protocol was applied on the arbitrarily chosen (R) enantiomer (in Appendix III).90 The initial MMFF 
conformational search resulted in five conformers in a 21 kJ/mol energy window, which were 
reoptimized at various DFT levels [B3LYP/6-31G(d) in vacuo, B97D/TZVP PCM/CHCl3 and CAM-
B3LYP/TZVP PCM/CHCl3] and ECD spectra were computed with B3LYP, BH&HLYP, CAM-B3LYP and PBE0 
functionals and TZVP basis set. The computed conformers differed in the orientation of the 6-OH 
proton and the C-8 vinyl group, the latter of which influenced the ECD spectra as well. The 1-OH group 
adopted equatorial position in all the computed conformers. All the applied combinations for all 
conformers reproduced the first two transitions at ca 422 and 375 nm and Boltzmann-weighted 
spectra acquired at all applied levels resembled also the high-energy transitions at ca. 227 and 206 nm 
allowing the elucidation of the absolute configuration as (R) for the first-eluting enantiomer (minor 
component) and (S) for the second-eluting enantiomer (major component). Interestingly, the 312 nm 
Cotton effect (CE) could not be reproduced by any applied combination of theoretical levels, which can 
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be attributed to difficulties in estimating the proper orientation of the conjugating quite freely rotating 
vinyl chromophore and the overlapping transitions of this region.91 
   
(S)-13 (25% ee) 14 15 
 Besides the new compound, luzulin A (LUB-3, 13), two dihydrophenanthrenes [juncusol (LUB-1, 
7) and juncuenin B (LUB-4, 6)], one phenanthrene [dehydrojuncuenin B (LUB-6, 11)] and two flavonoids 
[apigenin (LUB-9, 14) and luteolin (LUB-10, 15)] were obtained from L. luzuloides (Annex I). Their 
structures were identified by analyses of MS, 1D and 2D NMR data, and by comparison with literature 
data.25,99,102,103 
 Juncuenin B (JIN-3, LUB-4, 6), juncusol (JIN-5, LUB-1, 7) and dehydrojuncuenin B (JIN-11, LUB-6, 
11) were isolated from both J. inflexus and L. luzuloides. 
5.6. OXIDATION OF JUNCUENIN B 
Considerable amount of juncuenin B (6) (850 mg) has been isolated from J. inflexus, hence it can be 
considered as the main compound of the root, occurring up to 0.0243%. In our studies juncuenin B (6) 
and its unsaturated form, dehydrojuncuenin B (11) have been isolated from both J. inflexus and 
L. luzuloides. Luzulin A (13) from L. luzuloides and juncuenin D (8) from J. inflexus have obvious 
structure similarity with the abovementioned two phenanthrenes [juncuenin B (6) and 
dehydrojuncuenin B (11)], suggesting that both phenanthrenequinones are possibly derived from the 
oxidation of juncuenin B (6). In case of luzulin A (13), ring A is oxidized, while in case of juncuenin D (8) 
ring C has changed. In order to confirm their possible biosynthetic connection, juncuenin B (6) was 
subjected to an oxidative reaction by the use of hypervalent iodine reagent, 
[bis(trifluoroacetoxy)iodo]benzene (commonly known as PIFA)]. 
50.0 mg of juncuenin B (6) was dissolved in CH3CN–H2O (9:1, 50 mL), then 2 eq. PIFA (106.1 mg) 
was added to the solution in a careful manner to prevent sudden boiling. The reaction was monitored 
by TLC using cyclohexane–EtOAc–EtOH (20:10:1) as solvent system. After 30 min of stirring at room 
temperature all of the starting material, juncuenin B (6) was converted. Therefore, the mixture was 
cooled down in an ice bath, and evaporated at room temperature. Three major compounds were 
isolated from the mixture by NP-VLC, Sephadex LH-20 gel filtration and preparative TLC. 
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5.7. SEPARATION OF THE OXIDATIVE PRODUCTS OF JUNCUENIN B 
The concentrated mixture was chromatographed by NP-VLC on silica gel (sorbent: 10.0 g, column: 
25 mm × 100 mm) with a gradient system of CH2Cl2–acetone [from 99:1 to 7:3 (200 mL/eluent), and 
finally with MeOH (150 mL); volume of each collected fraction was 20 mL] to yield seven major 
fractions (1–7). Dehydrojuncuenin B (11) (8.9 mg) was purified from fraction 2 after gel filtration using 
MeOH–CH2Cl2 (3:1) as eluent [(60 mL); volume of collected fractions was 3 mL]. Fraction 4 was also 
separated by gel filtration with MeOH as eluent [(50 mL); volume of collected fractions was 2 mL] to 
afford three subfractions (4/1–3). From subfraction 4/2 luzulin A (13) (8.1 mg) was obtained by the use 
of NP-PLC using toluene–acetone (4:1) as solvent system. Juncuenin D (8) (11.2 mg) was isolated from 
fraction 6 after gel filtration using MeOH–CH2Cl2 (3:1) as eluent [(50 mL); volume of collected fractions 
was 2 mL]. The compounds were identified according to their TLC patterns and comparison of their 
1H NMR spectrum with literature data.25 
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6. DISCUSSION 
6.1. SCREENING STUDIES 
The aim of the work was to perform a screening study on the members of the Juncaceae family native 
to the Carpathian Basin for antibacterial and anti-inflammatory activity. Although some experimental 
evidence and ethnobotanical data have accumulated concerning the biological activity of Juncaceae 
species, no comprehensive screening studies have yet been published on the plants of this family.7-12 
The investigated Juncaceae species were collected in several regions of Hungary, Croatia and 
Romania. Among the selected species, previously only J. acutus and J. effusus were studied 
comprehensively from both phytochemical and pharmacological aspects.9,22-24,27-31 Moreover, 
carotenoids (lutein and β-carotin) and triterpenoids (β-sitosterol and stigmasterol) were obtained from 
J. gerardii.43 The flavonoid content of the stems and leaves of J. acutus, J. articulatus, J. conglomeratus, 
J. effusus, J. gerardii, J. inflexus, J. maritimus, J. squarrosus, J. tenuis, J. trifidus, L. campestris, L. forsteri, 
L. sudetica and L. sylvatica was reported earlier, but none of the plants (except J. acutus and J. effusus) 
were investigated extensively before our studies.42,49 
In the presented work, the antibacterial effects of 19 species belonging the genera Juncus (14) 
and Luzula (5) of the family Juncaceae were tested in vitro against ten multiresistant bacterial strains, 
by the use of disc-diffusion and microdilution methods. The plant samples, where it was possible, were 
separated into different plant organs, and extracted with an amphipolar solvent (MeOH), which 
permitted the isolation of lipophilic and polar components. Solvent–solvent partition was performed 
between n-hexane (extract A), CH2Cl2 (extract B), EtOAc (extract C) and the remaining H2O extract were 
named as extract D, to get altogether 96 fractions with different polarity. All fractions were screened 
for their antibacterial activity. According to the assays, several extracts showed anti-MRSA activity with 
mild to strong effectiveness. Sixteen extracts (extracts B and D) from Juncus species and three 
extracts B from Luzula species showed strong to moderate inhibitory activities against MRSA strains. 
Among them, extracts B of the roots of J. inflexus, and the roots of J. effusus showed remarkable 
activities. Extracts B of the whole plants of J. maritimus and J. gerardii displayed marked activities, and 
mild antibacterial activities were observed for the extract B of J. acutus and for the extract B of the 
aerial parts of J. tenuis. Weak antibacterial activities were recorded for L. campestris, L. forsteri and 
L. sylvatica. The differences between the chemical composition of genera Juncus and Luzula could 
serve as an explanation for the different activities. Up to now, much more phenanthrenes were 
reported from the species of genus Juncus, however the genus Luzula is far less studied than the genus 
Juncus. Previously, phenanthrenes were mainly isolated from the apolar fractions of the plants, 
therefore it was assumed that the majority of the antibacterial activity can be related to these 
compounds, but other compounds may also have influence on the overall activity.22 
37 
Extracts prepared from five Luzula species were evaluated for their anti-inflammatory activities 
by measuring their superoxide anion generation and elastase release inhibitory effects on human 
neutrophils. All of the investigated plants were found to be active. Among the fractions with different 
polarities, the CH2Cl2-soluble fractions had the most remarkable activities. All of the prepared fractions 
of L. luzuloides displayed remarkable activities in both assays. 
According to the preliminary screening results J. inflexus and L. luzuloides were chosen for 
further studies. 
Our comprehensive screening investigations on the selected Juncaceae species provided 
valuable data on the antibacterial and anti-inflammatory activities of numerous plants, which may 
contribute to the selection of other species for future pharmacological and phytochemical work. 
6.2. INVESTIGATION OF JUNCUS INFLEXUS AND LUZULA LUZULOIDES 
Chemical investigations of J. inflexus and L. luzuloides resulted in the isolation of 15 compounds, 
including five new (1–4 and 13) natural products. The structures were identified by means of spectral 
methods as phenanthrenes, 9,10-dihydrophenanthrenes, a diphenanthrene and flavonoids. 
Pharmacological analysis confirmed that some of the isolated compounds possess biological activity. 
6.2.1. Isolation of bioactive compounds 
Previous pharmacological investigations of the extracts with different polarity prepared from 
Juncaceae species (see sections 5.1 and 5.2) and reviewing the literature data led to the conclusion 
that mainly the lipophilic CH2Cl2 extracts contain the bioactive secondary metabolites. 
The air-dried plant materials were percolated with MeOH at room temperature and then 
solvent–solvent partition was performed to yield the apolar n-hexane and CH2Cl2 phases. In both cases, 
the CH2Cl2 phases were subjected to a series of chromatographic steps as well as a combination of 
several chromatographic techniques in order to isolate the compounds responsible for the 
pharmacological effects. 
The first fractionation of the CH2Cl2-soluble phase of J. inflexus was carried out by OCC, to afford 
four main fractions (J1–4); among them, fraction J3 was the most interesting from both phytochemical 
and pharmacological aspects. Since this fraction demonstrated great chemical complexity, more 
selective methods (VLC, MPLC) were applied on normal and reversed phase silica gel, and different 
solvent systems were used for gradient elution. The final purification of the pure compounds was 
performed by the use of NP-PLC, RP-PLC, GF, and RP-HPLC (1–12). 
The CH2Cl2 phase of the methanol extract of L. luzuloides was separated by polyamide OCC. The 
fraction obtained with MeOH–H2O 4:1 was subjected to multiple chromatographic separations, 
including VLC, Sephadex LH-20 gel chromatography and PLC, to yield six compounds (6, 7, 11, 13–15). 
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The preparative work was completed with analytical TLC on silica gel with various solvent 
systems. The detection was carried out in UV light at 254 and 366 nm, followed by spraying with 
vanillin-sulfuric acid reagent and heating at 120 °C for 5 min. 
6.2.2. Structure elucidation 
The chemical structures of the isolated compounds were determined by means of spectroscopic 
methods. The molecular masses and compositions were obtained from MS investigations; optical 
rotation measurements provided further important information for characterization of the 
compounds. The most useful data concerning the structures were provided by 1D and 2D NMR 
spectroscopy. The constitutions of the compounds were elucidated via 1H NMR, JMOD, 1H–1H COSY, 
HSQC and HMBC experiments, and the relative configurations were then characterized with the aid of 
NOESY spectra. As a result of the NMR studies, complete 1H- and 13C-assignments were made for the 
new compounds and also in the case of some known compounds, where previously published data 
were incomplete. The absolute configuration of the new compounds was determined by TDDFT-ECD 
calculations and enantiomeric purity was checked by chiral HPLC analysis. 
Eleven phenanthrenes were isolated from J. inflexus. Four compounds (jinflexins A–D, 1–4) are 
new natural products. Jinflexin A (1) is a methoxyethyl substituted 9,10-dihydrophenanthrene, which 
does not have a vinyl substitution, but the position of the methoxyethyl group suggests that 
biogenetically this component is originated from a vinylated compound. Its zero specific rotation and 
the baseline ECD spectrum adding to the results of the chiral HPLC analysis confirmed that jinflexin A 
(1) is a racemic mixture. Jinflexin B (2) is also specific, as its 9,10-dihydrophenanthrene core is 
substituted with an oxymethylene group at C-1. Moreover, it has a methoxy substitution at C-2, which 
is a quite unusual position for this group among Juncaceae phenanthrenes. Jinflexin C (3) is a carbonyl 
(C-1) substituted 5,6,9,10-tetrahydrophenanthrene, not only its core is unusual, but also the presence 
of a methyl and a vinyl group at the same carbon (C-7). On the basis of the TDDFT-ECD calculations and 
chiral HPLC analysis, jinflexin C (3) is a 6R,7R enantiomer with 80% ee. Jinflexin D (4) is a dimer with an 
unprecedented heptacyclic ring system, which may be considered to derive by the coupling of 2-
hydroxy-1,7-dimethyl-6-vinyl-phenanthrene (dehydrojuncuenin A, 9) with 2,7-dihydroxy-1,8-
dimethyl-5-vinyl-9,10-dihydrophenanthrene through their vinyl groups forming a unique structure. 
Distinct ECD spectrum could be recorded for jinflexin D (4), and the chiral HPLC analysis showed a 9% 
ee. The absolute configuration of the first-eluting enantiomer of 4 was identified as (R). The 
enantiomeric excess came from the second-eluting enantiomer, which was therefore determined as 
(S) enantiomer. Previously, phenanthrene dimers were published from J. acutus and J. effusus, but in 
those compounds neither or only one of the vinyl groups took part in the dimerization.23,29,79,80 Among 
the known phenanthrenes, six compounds can be paired, based on the saturation of the C-9–C-10 
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bond. The substitution pattern of dehydrojuncuenin A (9) and juncuenin A (5); dehydrojuncuenin B (11) 
and juncuenin B (6); dehydrojuncusol (10) and juncusol (7) are the same, the first member of the pairs 
are phenanthrenes, and the second ones are their 9,10-dihydro analogues. Juncuenin D (8) is a 
phenanthrenequinone presumably derived from juncuenin B (6) (see section 5.7). The absolute 
configuration of juncuenin D (8) was also determined, and its (S) enantiomer has 4% of enantiomeric 
excess. All of the phenanthrenes were isolated for the first time from the plant. In accordance with the 
previous screening focused on the flavonoid contents of the plant, chrysoeriol was also isolated.42 
The structure analysis of compounds isolated from L. luzuloides led to the identification of four 
phenanthrenes and two flavonoids. A new 1,6-dihydroxy-2-keto-1,7-dimethyl-8-vinyl-1,2-
dihydrophenanthrene (luzulin A, 13) was identified from the plant. Its chiral HPLC analysis and TDDFT-
ECD calculations suggested that luzulin A (13) is an (S) enantiomer, with 25% ee. Three known 
phenanthrenes [juncuenin B (6), juncusol (7) and dehydrojuncuenin B (11)] and two flavonoids 
[apigenin (14) and luteolin (15)] were also isolated from the apolar fraction of the plant. All of the 
compounds were identified for the first time in L. luzuloides, and this was the first time when 
phenanthrenes were isolated from a species belonging the genus Luzula. 
Among the isolated chiral compounds, jinflexin C (3), jinflexin D (4) and luzulin A (13) have 
quaternary stereogenic centers, which do not allow the inversion of the absolute configuration during 
the isolation. Therefore, the low enantiomeric excess can be attributed to the low enantioselectivity 
of the biosynthetic step, which has been observed for jinflexin D (4) and luzulin A (13) as well. 
6.2.3. Biosynthetic pathways 
The oxidative transformation of juncuenin B (6) led to the isolation of its possible biometabolites 
(Scheme 1). The compounds were identified as juncuenin D (8, 22%), dehydrojuncuenin B (11, 18%) 
and luzulin A (13, 16%) according to their TLC patterns and comparison of their 1H NMR spectrum with 
literature data.25 These findings confirm that the phenanthrenequinones, luzulin A (13) and juncuenin 
D (8), and the phenanthrene, dehydrojuncuenin B (11) can be formed by oxidation of juncuenin B (6), 
and most probably similar process may happen during their biosynthesis. 
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Scheme 1. Oxidation of juncuenin B (6) 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.4. Chemotaxonomy 
The isolation of vinylated phenanthrenes from L. luzuloides confirmed that phenanthrenes and 
flavonoids are the characteristic constituents of this plant. The secondary metabolite profile of 
L. luzuloides showed great similarity to that of the species of genus Juncus. The isolation of 
phenanthrenes, including a novel one from L. luzuloides highlighted that not only Juncus species can 
produce phenanthrenes in family Juncaceae, and Luzula plants are also promising starting materials 
for further phytochemical investigations. Our results confirmed the close chemotaxonomical 
relationship of the two genera. 
6.3. BIOACTIVITY OF THE ISOLATED COMPOUNDS 
6.3.1. Juncus inflexus 
In our preliminary screening the apolar extract of J. inflexus exerted the most potent antibacterial 
activity against MRSA strains. Therefore, it was subjected to a comprehensive preparative 
phytochemical analysis. The compounds isolated from this fraction were tested for their anti-MRSA 
activity at concentration of 10 mg/mL (Table 3). Among the isolated phenanthrenes, noteworthy 
inhibitory activities were recorded for jinflexin B (2), juncusol (7), juncuenin D (8), and 
dehydrojuncuenin B (11). Juncuenin D (8, inhibition zone = 12.0 ± 0.3 mm, MIC = 12.5 µg/mL) and 
PIFA, CH3CN–H2O 
30 min, rt 
8 
6 
11 
13 
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juncusol (7, inhibition zone = 12.0 ± 0.6 mm, MIC = 25 µg/mL) were the most potent in inhibition of 
MRSA (ATCC43300) growth, in accordance with previously reported studies.32,33 Moreover, 
dehydrojuncuenin B (11, inhibition zone = 10.0 ± 0.2 mm, MIC = 25 µg/mL) and jinflexin B (2, inhibition 
zone = 7.0 ± 0.1 mm, MIC = 100 µg/mL) possessed marked activity. Other compounds were proved to 
be inactive against MRSA. 
Table 3. Anti-MRSA activity of isolated compounds 
Compound 
MRSA (ATCC43300) inhibitory activity 
Inhibition (diameter of 
inhibition zone in mm) 
MIC 
(µg/mL) 
1 (jinflexin A) inactive  
2 (jinflexin B) 7.0 ± 0.1 100 
3 (jinflexin C) inactive  
4 (jinflexin A) inactive  
5 (juncuenin A) inactive  
6 (juncuenin B) inactive  
7 (juncusol) 12.0 ± 0.6 25 
8 (juncuenin D) 12.0 ± 0.3 12.5 
9 (dehydrojuncuenin A) inactive  
10 (dehydrojuncusol) inactive  
11 (dehydrojuncuenin B) 10.0 ± 0.2 25 
12 (chrysoeriol) inactive  
vancomycin* 15.5 ± 0.6 2 
*Positive control: vancomycin (5 µg/disc) 
6.3.2. Luzula luzuloides 
In the superoxide anion generation assay, significant inhibitory activities were recorded for juncuenin 
B (6) (IC50 = 4.92 µM), juncusol (7) (IC50 = 3.11 µM), dehydrojuncuenin B (11) (IC50 = 3.17 µM), apigenin 
(14) (IC50 = 6.12 µM) and luteolin (15) (IC50 = 4.73 µM). Furthermore, juncuenin B (6) and luteolin (15) 
inhibited effectively the elastase release with IC50s of 5.47 µM and 6.91 µM, respectively, comparable 
to that of the positive control LY294002 (IC50 = 4.79 µM). Juncusol (7), dehydrojuncuenin B (11) and 
apigenin (14) were considered to be inactive on the elastase release, while juncuenin D (8) and luzulin 
A (13) were proved to be inactive in both assays. 
These results indicated that the unsaturation of ring B in case of juncuenin B (6) resulted in the 
loss of the effect of the compound on the elastase release, but dehydrojuncuenin B (11) inhibits the 
superoxide generation slightly more effective than juncuenin B (6). The phenanthrenequinones, 
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juncuenin D (8) and luzulin A (13) presumably derived from juncuenin B (6), showed significantly lower 
anti-inflammatory activities compared to their possible biosynthetic precursor. 
Table 4. Inhibitory effects of the compounds on superoxide anion generation and elastase release on human 
neutrophils in response to fMLP/CB 
Compound 
Superoxide anion generation Elastase release 
IC
50
 (μM) Inhibition (%) IC50 (μM) Inhibition (%) 
6 (juncuenin B) 4.92 ± 0.27 81.54 ± 3.5*** 5.47 ± 1.11 80.57 ± 4.15*** 
7 (juncusol) 3.11 ± 0.25 93.07 ± 0.48*** > 10 2.05 ± 2.07 
8 (juncuenin D) > 10 43.29 ± 5.77*** > 10 32.75 ± 6.98** 
11 (dehydrojuncuenin B) 3.17 ± 1.19 82.90 ± 7.65*** > 10 25.58 ± 2.83** 
13 (luzulin A) > 10 12.26 ± 3.76* > 10 40.50 ± 5.57** 
14 (apigenin) 6.12 ± 0.72 73.92 ± 4.11*** > 10 46.14 ± 6.03** 
15 (luteolin) 4.73 ± 0.49 79.77 ± 4.37*** 6.91 ± 2.25 54.16 ± 4.66*** 
LY294002 1.29 ± 0.05 - 4.97 ± 0.80 - 
Percentage of inhibition (Inhibition %) at 10 μM concentration. Results are presented as mean ± S.E.M. (n=3–5). * P < 0.05, 
** P < 0.01, *** P < 0.001 compared with the control value. LY294002, a PI3K inhibitor, was used as positive control. 
6.4. HPLC-MS INVESTIGATION OF THE OCCURRENCE OF COMPOUNDS 
Bioassay-guided fractionation of J. inflexus resulted in the isolation of four phenanthrenes [jinflexin B 
(2), juncusol (7), juncuenin D (8), dehydrojuncuenin B (11)] with significant anti-MRSA activity (Table 3). 
The presence of these compounds was investigated by HPLC-MS in the most active Juncaceae extracts 
(CH2Cl2-soluble fractions of the roots of J. effusus and J. inflexus, whole plants of J. acutus, J. gerardii 
and J. maritimus, and aerial parts of J. tenuis) (Table 1). 
The detected active compounds could play an important role in the antibacterial effects of the 
extracts, which can involve different pharmacological mechanisms (Figure 7). Although juncusol (7) 
was detected in all the investigated extracts, and the presence of jinflexin B (2) was confirmed in the 
CH2Cl2-soluble extracts of J. acutus and J. gerardii, the chemical composition of J. gerardii, J. maritimus 
and J. tenuis were not studied thoroughly; therefore, some other, unidentified compounds may play a 
role in the activities of these extracts. 
All of the isolated compounds were detected in the CH2Cl2 fraction of J. inflexus, which suggests 
that these components were originally in the plant instead of evolving during the purification process. 
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Figure 7. HPLC chromatograms of plant extracts and identification of the bioactive compounds (2, 7, 8, 11) 
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7. SUMMARY 
The primary aim of the present work was the evaluation of antibacterial and anti-inflammatory effects 
of Juncaceae species native to the Carpathian Basin, and the isolation and structure determination of 
biologically active compounds from the most promising species, Juncus inflexus and Luzula luzuloides. 
Extracts with different polarity of 19 Juncaceae species were screened in vitro for their 
antimicrobial effects against methicillin-resistant S. aureus, extended-spectrum β-lactamase (ESBL)-
producing C. freundii, E. coli, E. cloacae, K. pneumoniae, multiresistant A. baumannii and P. aeruginosa 
by disc-diffusion and microdilution methods. According to the results Juncus inflexus was chosen for 
further studies. 
The Luzula species were assayed for their anti-inflammatory properties. The CH2Cl2-soluble 
fraction of Luzula luzuloides showed the most remarkable anti-inflammatory activities, it significantly 
inhibited the superoxide anion generation and the elastase release on fMLP/CB-induced human 
neutrophils. 
Pharmacological evaluations of the extracts with different polarity prepared from the collected 
species led to the conclusion that the lipophilic extracts (CH2Cl2) contain the most valuable bioactive 
secondary metabolites. Isolation of the compounds from these fractions was carried out by multistep 
separation procedures, including OCC, VLC, MPLC, PLC, GF and RP-HPLC. The structures of the isolated 
compounds were elucidated by means of spectroscopic methods (HRMS, MS and NMR). In addition, 
complete 1H and 13C NMR assignments were made for the characterization of the compounds. 
Four new natural phenanthrenes [jinflexin A (JIN-7, 1), jinflexin B (JIN-12, 2), jinflexin C (JIN-15, 
3) and jinflexin D (JIN-19, 4)] were isolated from the root parts of J. inflexus. Jinflexin C (JIN-15, 3) is a 
novel unusually substituted phenanthrenequinone, and jinflexin D (JIN-19, 4) is a dimer with a novel 
chemical skeleton containing a unique heptacyclic ring system. 
Besides the four new compounds, four dihydrophenanthrenes [juncuenin A (5), juncuenin B (6), 
juncusol (7), juncuenin D (8)], three phenanthrenes [dehydrojuncuenin A (9), dehydrojuncusol (10), 
dehydrojuncuenin B (11)], and the flavonoid chrysoeriol (12) were also obtained from the plant. In 
cases of jinflexin A (1), jinflexin C (3), jinflexin D (4) and juncuenin D (8) the absolute configurations 
were also determined. 
Four phenanthrenes possessed remarkable inhibitory activities against MRSA strains. Juncusol 
(7) and juncuenin D (8) displayed significant activity, moreover marked activity were recorded for 
jinflexin B (2) and dehydrojuncuenin B (11). The HPLC-MS investigation of the chemical composition of 
other significantly active Juncaceae extracts revealed the presence of juncusol (7) in all the investigated 
extracts, and the presence of jinflexin B (2) in some cases. Species belonging to the genus Juncus, 
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especially J. gerardii, J. maritimus and J. tenuis are promising candidates for further activity-guided 
fractionation in the search for new active antibacterial natural compounds. 
The apolar extract of L. luzuloides exerted noteworthy anti-inflammatory activity in vitro. 
Comprehensive preparative phytochemical work resulted in the isolation of a new 
phenanthrenequinone, luzulin A (13), three known phenanthrene derivatives [juncuenin B (6), juncusol 
(7) and dehydrojuncuenin B (11)] and two flavonoids [apigenin (14) and luteolin (15)] from the plant. 
This was the first time that phenanthrenes were detected from a Luzula species, which could confirm 
that besides flavonoids, phenanthrenes could also serve as chemotaxonomic markers for Luzula 
species and prove the close relationship of genera Juncus and Luzula. 
The oxidative semi-synthetic transformation of juncuenin B (6) led to the isolation of its possible 
biometabolites: juncuenin D (8), dehydrojuncuenin B (11) and luzulin A (13). 
The superoxide anion generation and the elastase release inhibitory activities of the isolated 
compounds (6–8, 11, 13–15) were tested on fMLP/CB-induced human neutrophils. Noteworthy anti-
inflammatory activities were recorded for juncuenin B (6), juncusol (7), dehydrojuncuenin B (11), 
apigenin (14) and luteolin (15). Although great deals of phenanthrenes were assayed for their anti-
inflammatory properties, this was the first time when the anti-inflammatory activity of the isolated 
phenanthrenes was evaluated. The traditional use of Juncaceae plants against inflammatory diseases 
seems to be supported by our data. 
All of the isolated compounds were detected for the first time from the investigated plants. The 
chemical constituents of J. inflexus and L. luzuloides have not been investigated previously. 
The methyl group at C-1, a hydroxy group at C-2 and vinyl, methyl and hydroxy substitution on 
ring C are characteristic features of the isolated phenanthrenes. In compounds 3, 8 and 13, a carbonyl 
group can be found in the molecule. 
Vinyl substituted derivatives can be considered as chemotaxonomic markers for plants 
belonging to family Juncaceae, since these specifically substituted phenanthrenes were reported 
previously only from Juncus species, and this was the first time when they were isolated from the genus 
Luzula. The chemical characterization of L. luzuloides, and the presence of vinylated phenanthrenes in 
the plant further confirm the close botanical relationship between the genera Juncus and Luzula. 
Our preliminary screen has provided important data on the antibacterial and anti-inflammatory 
properties of numerous Juncaceae species native to the Carpathian Basin, which promotes the 
selection of further species for future pharmacological and phytochemical work. The results reveal that 
secondary metabolites of Juncaceae species can be regarded as promising starting materials in the 
search for new pharmaceutical discoveries, in consequence of their pharmacological potential, and in 
particular their noteworthy antibacterial and anti-inflammatory activities. 
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Annex I. Structure of the isolated compounds 
 
   
jinflexin A (1) jinflexin B (2) jinflexin C (3) 
     
jinflexin D (4)    juncuenin A (5)   juncuenin B (6) 
   
juncusol (7) juncuenin D (8) dehydrojuncuenin A (9) 
   
dehydrojuncusol (10)   dehydrojuncuenin B (11) chrysoeriol (12) 
   
luzulin A (13) apigenin (14)   luteolin (15) 
  
 
 
Annex II. NMR data of jinflexin A (1) [DMSO-d6, 500 MHz (1H), 125 MHz (13C), δ (ppm), J = Hz], and 
jinflexin B (2) [CD3OD, 400 MHz (1H), 100 MHz (13C), δ (ppm), J = Hz] isolated from J. inflexus 
position 
1  2 
1H 13C HMBCa  1H 13C 
1  120.2, C    125.9, C 
1a  138.8, C    141.7, C 
2  153.7, C    157.4, C 
3 6.70, d (8.0) 111.6, CH 1, 4a  6.78, d (9.2) 108.2, CH 
4 6.84, d (8.0) 126.0, CH 1a, 2  7.65, d (8.7) 131.8, CH 
4a  125.3, C    129.4, C 
5  137.5, C    137.9, C 
5a  126.8, C    127.0, C 
6 6.86, s 110.5, CH 5a, 8   122.2, C 
7  153.8, C    155.1, C 
8  119.6, C   6.64, s 113.7, CH 
8a  138.1, C    138.6, C 
9 2.32, 2H, m  26.3, CH2   2.59, 2H, m 31.4, CH2 
10 2.75, 2H, m  25.3, CH2   2.80, 2H, m 26.6, CH2 
11 2.13, s 11.6, CH3 1, 1a, 2  4.76, 2H, s 55.9, CH2 
12 4.69, d (4.9) 74.5, CH 5a, 6, OMe-12  6.83 dd (18.6, 11.6) 139.2, CH 
13 1.47, d (4.9) 23.2, CH3 5, 12  5.43 dd (11.4, 1.1), 
5.13 dd (18.0, 1.0) 
119.5, CH2 
14 2.10, s 11.7, CH3 7, 8, 8a  2.21, s 13.6, CH3 
OH 9.23, s      
OH 9.17, s      
2-OMe     3.84, s 56.1, OCH3 
12-OMe 2.85, s 55.0, CH3 12    
aHMBC correlations are from proton(s) stated to the indicated carbon. 
 
  
 
 
Annex III. NMR data of jinflexin C (3) [CD3OD, 400 MHz (1H), 100 MHz (13C), δ (ppm), J = Hz] isolated 
from J. inflexus, and luzulin A (13) [CD3OD, 500 MHz (1H), 125 MHz (13C), δ (ppm), J = Hz] isolated from 
L. luzuloides 
position 
3  13 
1H 13C  1H 13C HMBCa 
1  123.1, C   78.1, C  
1a  140.1, C   146.6, C  
2  159.4, C   207.1, C  
3 6.71, d (8.5) 113.6, CH  6.25, d (10.2) 123.1, CH 1, 4a 
4 7.23, d (8.6) 125.2, CH  8.35, d (10.1) 141.9, CH 1a, 2 
4a  126.4, C   122.6, C  
5 2.98, m; 2.72, m 33.6, CH2  7.52, s 103.3, CH 4a, 6, 8a 
5a  149.4, C   132.2, C  
6 3.88, dd (9.6, 4.5) 74.4, CH   157.0, C  
7  55.5, C   126.3, C  
8  201.9, C   138.3, C  
8a  128.8, C   127.7, C  
9 2.65, m; 2.24, m 21.1, CH2  8.12, d (8.5) 129.8, CH 1a, 5a 
10 2.84, m; 2.57, m 25.1, CH2  7.63, d (8.7) 121.0, CH 4a, 8a 
11 2.15, s 11.4, CH3  1.53, s 32.1, CH3 1, 1a, 2 
12 6.10, dd (17.7, 10.8) 138.1, CH  2.35, s 13.4, CH3 6, 7, 8 
13 5.13, d (10.8), 
4.90, d (17.7) 
116.5, CH2  7.05, dd (17.9, 11.5) 135.7, CH  
14 1.32, s 20.2, CH3  5.81, d (11.5), 
5.35, d (18.0) 
122.2, CH2 8 
aHMBC correlations are from proton(s) stated to the indicated carbon. 
  
 
 
Annex IV. NMR data of jinflexin D (4) isolated from J. inflexus [DMSO-d6, 500 MHz (1H), 125 MHz (13C), 
δ (ppm), J = Hz] 
position 
4 
1H 13C HMBCa 
1  117.1, C  
1a  131.6, C  
2  152.9, C  
3 7.02, d (8.9) 116.4, CH 1, 2, 4a 
4 7.59, d (9.0) 119.9, CH 1a, 2, 5a 
4a  122.7, C  
5 7.69, s 120.3, CH 4a, 7, 12 
5a  128.0, C  
6  141.6, C  
7  133.2, C  
8 7.67, s 128.8, CH 5a, 6, 9, 14 
8a  128.1, C  
9 7.64, d (9.2) 126.1, CH 1a, 5a 
10 7.74, d (9.2) 121.7, CH 1, 1a, 4a 
11 2.41, s 10.9, CH3 1, 1a, 2 
12 4.90, d (8.6) 32.0, CH 5, 5′, 6, 6′, 7, 7′, 13, 13′ 
13 2.85, m; 2.40, m 28.7, CH2 6, 6′, 12, 12′, 13′ 
14 2.68, s 19.3, CH3 6, 7, 8 
1′  120.3, C  
1a′  138.5, C  
2′  153.9, C  
3′ 6.77, d (8.3) 111.6, CH 1′, 2′, 4a′ 
4′ 7.13, d (8.3) 127.1, CH 1a′, 2′, 5a′ 
4a′  125.4, C  
5′  128.4, C  
5a′  125.7, C  
6′  124.5, C  
7′  149.8, C  
8′  121.4, C  
8a′  136.5, C  
9′ 2.91, dt (4.3) 
2.36, m 
26.1, CH2 1a′, 5a′, 8′, 8a′, 10′ 
10′ 2.98, dt (4.1) 
2.50, m 
25.3, CH2 1′, 1a′, 4a′, 8a′, 9′ 
11′ 2.26, s 11.7, CH3 1′, 1a′, 2′ 
12′ 6.96, dd (9.7, 2.7) 128.0, CH 6′, 13 
13′ 5.71, ddd (9.7, 7.1, 2.1) 122.8, CH 5′, 12, 13 
14′ 2.09, s 12.6, CH3 7′, 8′, 8a′ 
aHMBC correlations are from proton(s) stated to the indicated carbon. 
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